TITLE PAGE

Title:

Re-analyzed *APOL1* kidney data support new ethics of 'race'

Authors:
Cyril O. Burke III[1*], Joshua Ray Tanzer[2], John G. Toffaletti[3,4], Leanne M. Burke[5]

[1] Department of Neurology, Brown University Health, Providence, Rhode Island, United States of America

[2] Biostatistics, Epidemiology, Research Design, and Informatics Core, Brown University Health, Providence, Rhode Island, United States of America

[3] Department of Pathology/Clinical Laboratories, Duke University Medical Center, Durham, North Carolina, United States of America

[4] Department of Clinical Chemistry, Veterans Administration Medical Center, Durham, North Carolina, United States of America

[5] Cardiovascular Institute, Brown University Health, Providence, Rhode Island, United States of America

[*] *corresponding author:*
E-mail: cyrilburke@alum.mit.edu (cob3)



ABSTRACT

OBJECTIVES

Research on ‘racial’ differences and racialized diseases often stresses genetics over social conditions, perhaps because some medical journals limit (or exclude) as social ‘Commentary’ discussion of ‘race’ as a proxy for social determinants of health. Yet, anthropology research shows that ‘race’ is socially constructed. From before birth, persistent US ‘racial’ segregation racializes health, education, employment, and access.

We hypothesized that selective recruitment into US military service, equal opportunity for military training and jobs, and earned access to Veterans Administration Healthcare could mitigate ‘racial’ differences created by racialized early-life deprivations and harms (i.e., social determinants of health). We examined veteran status and the starkest ‘racial’ disparity in healthcare—chronic kidney disease.

METHODS

First, we defined terms to ensure cross-cultural clarity by orienting international colleagues to the semantics of socially constructed ‘race’ (in Europe) and overt and subtle racialization of health (in the US). Second, we removed ‘race correction’ from estimated glomerular filtration rate and kidney failure under more equal conditions of US veterans. Third, we used data re-analysis and close examination of social cofactors to suggest alternative mechanisms for links between socially constructed ‘race’, apolipoprotein L1 gene variants, and racialized kidney disease.

RESULTS

Our research found no ‘racial’ disparity in kidney failure under more equal social conditions and that geographically localized “ancestry markers” may proxy for ‘race’. ‘Colorism’ may be associated with apolipoprotein L1 variants linked to ‘racial’ (e.g., pigmentary) genes.

CONCLUSIONS

Under equal conditions, comparable outcomes should be the expected norm for all, regardless of socially constructed ‘race’, ethnicity, or nationality. Disparity between socially constructed categories implies disparate social conditions. International collaboration to discourage misuse of socially constructed ‘race’ in medical care and research is an actionable Population Health initiative with potentially high impact but low effort and cost.

STRENGTHS OF THIS STUDY

1. Reminds readers of cross-cultural conflicts in socially constructed ‘race’.
2. Introduces international observers to racialization of health in the US.
3. Re-analyzes socially constructed ‘race’ under more equal conditions.
4. Applies new ethics, recommended by the National Academies of Sciences, Engineering, and Medicine, to older research on socially constructed ‘race’.

KEYWORDS

Apolipoprotein L1; *APOL1*; Bad science; Chronic kidney disease; CKD; Ethical Review; Ethics Committee; Institutional Review Board; IRB; Justice; N264K; Race; Racial; Racism; Social determinants of health; SDOH; Veteran; Veterans.

ABBREVIATIONS

AKI = acute kidney injury, *APOL1* = apolipoprotein L1, BS = bad science, CKD = chronic kidney disease, COVID = coronavirus disease, eGFR = estimated GFR, FSGS = focal segmental glomerulosclerosis, GFR = glomerular filtration rate, GWAS = genome-wide association study, HR = high risk, LR = low risk, IRB = institutional review board, KF = kidney failure, MDRD = Modification of Diet in Renal Disease, NASEM = National Academies of Sciences Engineering and Medicine, OR = odds ratio, RR = relative risk, RV = risk variant, SDOH = social determinants of health, VA = Veterans Administration.

1. INTRODUCTION

NOTE: An eminent European nephrologist insisted that our study (to reduce US 'racial' disparity in kidney disease) separate discussion of 'race' from serial creatinine: "The race part is irrelevant for the key point (race does not change over time, and thus is not relevant when looking at longitudinal serum creatinine or eGFR) and should be deleted in the opinion of this reviewer". After multiple rounds of review, we relented. The sister article added 'race-free' diagnosis of prechronic kidney disease using within-individual referencing of serial creatinine [1].

Unchallenged for 'racial' inconsistency and selectively including or overlooking its influence, medical research can unwittingly promote 'racial' illusions that advance the myth of 'race' as biology. Hunt et al noted,

> …current health literature encourages clinicians to see their patients through a racial lens…. [T]he systematic inequalities that have been observed in the clinical care that racialized patients receive (Smedley et al. 2003) likely reflect more than structural inequalities alone. They may also be attributable to this systematic authorization of race-based care. The arbitrary and contradictory ways the clinicians in this study understand and apply the concept of race raise concern that not only does using race to inform diagnostic and treatment choices lack scientific rigor, it may also put patients at risk of receiving nonstandard care [2].

The persistent use of socially constructed 'race' in US healthcare may seem unbelievable to decent, well-meaning international colleagues. That denial creates a stubborn obstacle to ending misuse of 'race'. Before our **Results** and **Discussion**, we offer this **Introduction** (with European and US examples) to orient international readers to the illusions of socially constructed 'race' and 'ethnicity' that inspire bad science (BS) in racialized countries.

1.1 'Race' and ethnicity

"Race" and "ethnicity" are commonly used to describe population groups. Yet, their socially constructed meaning has changed over time and between countries, and hidden assumptions may limit understanding by international colleagues.

In "The meaning of racial or ethnic origin in EU law", the European Commission noted:

> In EU law, the Racial Equality Directive (RED) prohibits discrimination on the grounds of racial or ethnic origin without defining them…. In Europe, most groups targeted by racism categorically reject race as a label. Still, racialisation as 'a process that ascribes physical and cultural differences to individuals and groups' is thriving….
>
> Without real physical differences, people can be racialised on the basis of their perceived religiosity: the dress they wear or the way they cover their hair. Theories of Christianity's superiority over the Jewish and Muslim faiths can be traced back over centuries of European

> civilisation, and they laid the ground for anti-Semitism and Islamophobia. Poverty, too, can be portrayed as having its own culture, language and value system, thus poverty can also be racialised – particularly if a visible proportion of poor people belong to racial minorities….
>
> The traumatic experiences of the Holocaust and the urge to respond to apartheid provoked the scientification of race in legal terminology, which trapped racial in the confines of biological racism – the essence of the ideologies it originally set out to combat. Scientification disassociated racial from nation(al minority) and consequently severed cultural, religious and linguistic from it. Reducing the meaning of racial to 'biological' inevitably paved the way to essentialisation, while insulating it from the influence of social sciences….
>
> The invention of a supercategory with the intention of ensuring terminological unity and dispelling scientific misconceptions of race and racial origin at the international level had an unintended side effect in Europe. Here, the prism of nationalism resists the smooth transfer of terminological reform that followed WWII. While in **France**, ethnic origin is perceived as equivalent to race, in the **UK** it is separately defined in case law. In the rest of the EU, correlations between ethnic and racial occupy a central place in academic discussions and judicial interpretation [3].

Because everyone is confident in the local meaning of 'race', agreement on socially constructed 'race' between co-located subject and observer reflects 'shared illusion' rather than scientific "validity" [4,5,6,7].

In 2022, Lu et al summarized contradictions and uncertainties in socially constructed 'race' and ethnicity [8]. They noted **(1)** lack of "consensus definition of race or ethnicity", **(2)** inconsistency between subject and observer identification for other than Black or White 'race', and **(3)** "fluidity" of self-identification. Their aspirational recommendations called for "specific definitions" and "justification for collecting and analyzing" data on socially constructed 'race' in health research.

Subsequently, in a 2023 report on "Using Population Descriptors in Genetics and Genomics Research", the National Academies of Sciences, Engineering, and Medicine (NASEM) stated:

> Race is neither useful nor scientifically valid as a measure of the structure of human genetic variation….
>
> Over the past several decades, a number of professional societies have developed statements or guidelines on race, ethnicity, human diversity, and multicultural practices…. In every case, the guidelines have been aspirational and intended to encourage their professional colleagues to become educated and informed….
>
> Despite the many recommendations, guidelines, and strategies… there has been relatively little change in how any entities within the genetics and genomics research ecosystem use these descriptors or require them to be used [9].

1.2 Racialized US healthcare

Although it often provides 'the best healthcare in the world', US healthcare ranked last among high-income countries [10] and 48th of 50 nations for kidney-related mortality [11], **Fig 1**.



Fig 1. Age-standardized kidney disease death rate per 100,000 in 50 selected countries (2017).

About 1.8% of total federal spending went to chronic kidney disease (CKD) and kidney failure (KF) [12], almost doubling in a decade to $122 billion [13], **Fig 2**. Fragmented US healthcare spends more per capita than any other nation [14], yet "low-income minorities with bad health had 68% less odds of being insured than high-income Whites with good health" [15]. There are numerous "racially segregated US hospital markets" [16]. At some academic centers, Black patients were more likely to be deemed "teaching cases" for training the medical students, residents, and fellows. In 2003, the National Academy of Medicine reported on "Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care" [17], but 20 years later, "There hasn't been a lot of progress…. We are still largely seeing what some would call medical apartheid" [18].



Fig 2. Medicare spending on chronic kidney disease (CKD) and kidney failure (KF).

1.2.1 'Racial' profiling, hypertension, kidney disease

In the US, CKD and KF represent the eighth leading cause of death, with lifetime risk varying by socially constructed 'race' and ethnicity [19,20], **Fig 3**, "one of the starkest examples of racial/ethnic disparities in health" [21].



Fig 3. Lifetime risk of death, selected causes. Solid and striped bars show kidney failure (KF) death rates by US 'race' and ethnicity. Clear bars are rates for other causes (combined sexes).

Black people are 12% of the population but 35% of patients on dialysis. Kidney disease mortality rates per 100,000 across the 30 most populous US cities averaged 12.4 for White and 28.2 for Black patients but with marked geographic disparities: White patients, from 2.0 in San Diego, California, to 18.2 in Louisville, Kentucky; Black patients, from 7.9 in New York City, to 45.4 in Charlotte, North Carolina [22].

Ending 'racial' disparity in kidney disease for Black patients alone could redirect 20% of federal funds—$25 billion annually—from late-stage CKD to prevention [23].

Conversely, data collected to monitor and remedy 'racial' disparities can worsen them, for example, by misuse in clinical algorithms [24] and popular point-of-care clinical decision-making tools [25,26]. Hunt and Kreiner studied the effect on primary care and noted:

> …that racial/ethnic group differences are so readily equated with presumed genetic differences, and that the idea of "Personalized Medicine" can so ironically be converted into carte blanche for practicing racialized medicine [27].

Despite originating from various continents, studies under similar social conditions are relevant worldwide, regardless of the 'race' of the subjects (or lack of contrasting 'races'). Recruiting 'racially diverse' subjects into medical research merely allows tracking of disparate treatment from lingering 'racial' segregation and structural racism.

However, some studies misuse 'racial' disparities as evidence for the myth of 'race', and others may not report outcomes by 'race'. For example, US treatment guidelines for hypertension favor thiazide diuretics for Black patients [28,29]. A study that cautioned against diagnosing KF while on thiazides noted usage ratios of thiazide to loop diuretics of 1.06 for White and 1.65 for Black subjects but did not report KF by 'race' [30]. A study promoting reduced cardiovascular mortality by controlling systolic blood pressure to less than 120 mm Hg showed no benefit for its Black subjects [31] but did not report their 100% increase in acute kidney injury (AKI) until years later [32]. Despite racialized prescribing of thiazides, another study recommending chlorthalidone for poorly controlled hypertension in advanced CKD noted that on the thiazide, the number of subjects with AKI tripled (and AKI episodes per subject increased by 50%) but failed to report AKI by 'race' [33]. Note: dehydration causes more AKI in low-income areas [34],

increases CKD risk [35] (as does AKI), and is prevalent among Black people [36], possibly interacting with thiazide use.

1.2.2 'Race correction'

In 1999, the Modification of Diet in Renal Disease (MDRD) equation for estimating glomerular filtration rate (GFR) introduced the first 'race correction' for estimated GFR (eGFR) [37]. More eGFR 'corrections' followed—for ethnicity in the US [38] and nationalities in Asia [39,40,41,42]. Laboratory reporting that some eGFR results were 'race corrected' led to questioning of the practice [43,44], and the "…majority of studies found that removal of race adjustment improved bias, accuracy, and precision of eGFR equations for Black adults" [45].

Discussing misuse of 'race' in nephrology, Eneanya et al distinguished mistreating individuals versus monitoring the effects of racism on a population and noted that "race should not be used to make any biological inferences about individuals". However, they conceded, "the notion that the use of a Black race coefficient in eGFR equations contributes to health inequity for Black patients has not been universally accepted" [46].

In 2023, two years after the creation of "race-free" equations, some researchers described opposition to eGFR 'race correction' "…through the lens of clashing values":

> the activists had a strong moral case…. However, there was lack of acknowledgment for data showing that considering race does improve GFR estimation [47].

Reports that the ostensibly "race-free" eGFR equations "underestimated measured GFR in Black participants… and overestimated measured GFR in non-Black participants" [48] merely shifted misuse of 'race' from the equations to conscious and unconscious pre-test "population weighting" [49,50], which is much harder to detect and stop.

1.2.3 Motivation and outcomes

Kuhn presented 'science' as inherently social, demonstrating how the solutions of today (or yesterday) become the problems of tomorrow (or today) [51]. Articles discussing socially constructed 'race' as a proxy for social determinants of health (SDOH) are often labeled social 'Commentary' [52]. Articles proclaiming the objectivity of numbers [53], and that "…a race stratified eGFRcr (i.e., separate equations for Blacks and non-Blacks) would provide… the best medical treatment for all patients" [54], miss how 'Confirmation Bias' influences what numbers we collect, how we understand that data, our confidence in what we are doing now, and which articles get published.

Racialized practices—ongoing despite 100 years of scholarly articles in Anthropology that 'race' is a myth—inspired our data re-analysis (see **Results**) and examination of socially constructed 'race' as a proxy for implied social cofactors (see **Discussion**). To end misuse of 'race' is an overdue Kuhnian paradigm shift [51,55,56].

"With malice toward none, with charity for all" [57], we re-examined 'race' in kidney disease. Removing 'race correction' from GFR estimates of Black and White veterans showed comparable results. Re-analyzing two studies of gene variants associated with kidney risk in Black veterans—both published before NASEM guidance [9]—gave insights into the influence of socially constructed 'race'.

2. RESULTS

2.1 Removing ‘race correction’

Removing ‘race correction’ from GFR estimates of an impressive study of KF versus eGFR in 1.70 million White veterans (4% female) and 311,000 Black veterans (6.1% female) [58] tested our hypothesis that differences between arbitrary groups would be less after comparable conditions of selection and opportunity.

2.1.1 Equal outcomes despite ‘race’

Fig 4 shows baseline veteran characteristics and renal comorbidities (all significant to p<0.001), with Black veterans more likely to be younger, female, hypertensive, diabetic, in the highest and lowest eGFR ranges, and living in lower-socioeconomic-status zip codes **(left)**, the latter also shown graphically **(right)**.

Baseline Characteristics of Outpatient Veterans by 'Race'

Characteristic	Black	White
Total (%)	311,790 (15.5)	1,704,101 (84.5)
Age, mean ± standard deviation (years)	59.1 ± 13.8	**66.0 ± 12.4**
Female Sex (%)	**6.1**	4.0
Estimated glomerular filtration rate, mL/min/1.73m2 (%)		
≥90	**44.2**	21.5
60-89	42.5	**56.3**
45-59	8.2	**15.2**
30-44	3.3	**5.5**
15-29	1.4	1.4
<15	**0.4**	0.2
Comorbidities (%)		
Hypertension	**70.5**	67.7
Diabetes mellitus	**31.5**	29.1
Coronary heart disease	25.7	**39.4**
Chronic obstructive lung disease	23.3	**30.0**
Stroke or transient ischemic attack	12.3	**15.6**
Heart failure	12.0	**15.8**
Peripheral arterial disease	10.7	**15.4**
Dementia	**5.6**	5.5
Hepatitis C virus infection	**5.3**	2.1
Atrial fibrillation	4.8	**10.6**
Human immunodeficiency virus infection	**2.6**	0.4
Socioeconomic status (SES), tertile (%)		
Low	**55.6**	29.9
Middle	24.6	**35.0**
High	19.8	**35.2**

Comorbidities ranked by frequency in Black veterans. Bold type marks higher prevalence of each comorbidity in Black or White veterans (p<0.001 for all) and diabetes mellitus and hypertension as the major risk factors for chronic kidney disease. Residential zip code allowed crude estimatation of each subject's SES.



Fig 4. Left panel: Baseline characteristics of veterans in the primary source by ‘race’, all cofactors with p<0.001. **Right panel:** Graphic of veteran socioeconomic status, approximated (in the primary source) by zip code.

Mathematically removing the MDRD eGFR ‘race correction’ for Black veterans (dividing by 1.21) shifted rates for KF risk and eGFR prevalence to lower GFRs, **Fig 5**, also shown graphically in **Fig 6**. The x-axis ‘race corrections’ (horizontal arrows) sometimes had significant y-axis effects (vertical arrows). The revised KF outcome curves (increasing to the left) overlapped for Black and White veterans (inset). The revised eGFR-prevalence curves (increasing to the right) showed higher prevalence of lower eGFRs in Black veterans. Under similar conditions, the paradox of low prevalence of early CKD yet faster progression at late stages appeared to be a mathematical artifact of ‘race correction’.

Removing 'race' from primary data, 1st and 2nd tables						
4-variable MDRD estimated glomerular filtration rate, mL/min/1.73m^2 (%)						
Range of eGFRs	Upper limit of eGFR	White		Black		
		Percentage	Cumulated %	Limit / 1.21	Percentage	Cumulated %
≥90	undefined	21.5	100	undefined	44.2	100
60-89	90	56.3	78.6	74.4	42.5	55.8
45-59	60	15.2	22.3	49.6	8.2	13.3
30-44	45	5.5	7.1	37.2	3.3	5.1
15-29	30	1.4	1.6	24.8	1.4	1.8
<15	15	0.2	0.2	12.4	0.4	0.4
Age-standardized rates of kidney failure (per 1,000 person-years)						
Range of eGFRs	Upper limit of eGFR	White		Black		
		KF rate (95% CI)		Limit / 1.21	KF rate (95% CI)	
≥90	undefined	0.2 (0.1, 0.3)		undefined	0.4 (0.2, 0.6)	
60-89	90	0.1 (0.1, 0.2)		74.4	0.4 (0.3, 0.4)	
45-59	60	1.7 (1.5, 1.8)		49.6	6.3 (5.7, 7.0)	
30-44	45	12.5 (11.8, 13.1)		37.2	32.8 (30.4, 35.2)	
15-29	30	94.3 (90.7, 97.9)		24.8	179.5 (169.8, 189.3)	
<15	15	472.3 (448.3, 496.4)		12.4	615.6 (571.0, 660.3)	

Note: Numbers in parentheses are limits of the 95% confidence interval. **ABBREVIATIONS: CI = confidence interval, cumulated % – sum of percentages of eGFRs (y-axis) below the upper limit (x-axis), eGFR – estimated glomerular filtration rate, KF = kidney failure, MDRD = Modification of Diet in Renal Disease, mL/min = milliliters per minute.**

Fig 5. Removing 'race correction'. Dividing the upper limit of eGFR range for Black patients by the 1.21 'race correction' numerically removed 'race correction', shifting their results to lower numbers on the x axis. In a table, the result is not striking. Note: "end-stage renal disease" (ESRD) is the US equivalent of kidney failure (KF).



*** = Age-standardized events per 1,000 person-years,** ** = Sum of percentages in lower eGFR ranges.

Fig 6. Removing 'race correction' graphically. On these graphs, the 1.21 multiplier in the Modification of Diet in Renal Disease (MDRD) eGFR equation had shifted results for Black patients to the right (solid black curves). Removing 'race correction' (i.e., dividing by 1.21) shifted the results back to the left (blue curves) with no effect on y-axis values of those data points but revealing the effective x-axis and y-axis shifts indicated by the horizontal and vertical black arrows. **Curves increasing to the left** show that removing 'race correction' shifted kidney failure (KF) rates for Black veterans to within the 95% confidence interval of the curve for White veterans (inset). **Curves increasing to the right** show that 'race correction' for Black veterans falsely lowered the cumulated percentages below each eGFR 'limit' (y-axis), the difference between the solid blue and black curves.

This visual examination was supported analytically. When estimating magnitude of associations between inverse eGFR and KF rates with and without 'race correction', the ratio was exactly 1.21, as expected ('race corrected': beta = 11700.74; correction removed, beta = 9670.03; ratio = 1.21). Additionally, as hypothesized, White and Black patients had more similar associations between serum creatinine and GFR after removing the 'race correction' (t (10) = 0.91, p = 0.3860) than when 'race correction' was maintained (t (10) = 2.36, p = 0.0402). The sample size was small—only 15 data points—because continuous raw data was broken (dichotomized) into five segments, yielding five data points each for White veterans and Black veterans with and without 'race correction'—therefore, the precision of this result may not hold up with replication. However, it validates concerns raised about an artifact of arithmetic resulting in differences in kidney disease diagnosis. It contradicts notions that Black Americans have less early CKD and need less early care.

2.2 *APOL1*, AKI, and COVID

Hung et al studied the effects of apolipoprotein L1 (*APOL1*) risk variant (RV) alleles among 990 participants in the Department of Veterans Affairs Million Veteran Program with "African ancestry" and hospitalized with coronavirus disease 2019 (COVID-19) [59]. **Fig 7** shows AKI rates with and without various cofactors, ordered by odds ratios (ORs). They found the relative risk (RR) of AKI was 1.35 times higher for *APOL1* "high-risk" (HR) genotype (*APOL1* HR = 2 RV copies) than "low-risk" (LR) genotype (*APOL1* LR = 0 <u>or</u> 1 RV copy). However, RR of AKI was 2.4 for mechanical ventilation and 2.63 for vasopressor use, both more common in the *APOL1* HR group.



Fig 7. Acute kidney injury rates for various cofactors in veterans hospitalized with COVID-19. Possible direct or indirect AKI cofactors ordered by odds ratios (ORs), the greatest risk correlating with indicators of poor health.

ORs make the comparison more explicit, **Fig 8**. We also included data from a similar study of COVID-19 and AKI in the Brazilian general population [60]. Although recalculated confidence intervals are much wider for the Brazilian sample, the ORs between Brazil and the US are close for many cofactors.

Odds ratios by AKI cofactor in US veterans (•) and Brazilians (▫) hospitalized with COVID



Fig 8. Acute kidney injury (AKI) odds ratios (ORs) for cofactors during hospitalization with COVID-19. Forest plot of AKI ORs (with 95% confidence intervals) suggests similarity of cofactors between US veterans and Brazilian general population despite their differences in genetic origins and socially constructed 'race'.

Many covariates showed statistically "small" effects (ORs below 1.68), some small enough to suggest random chance. Signs of critical illness showed "large" effects (OR above 6.71). Urine characteristics had ORs primarily toward the upper range, highlighting their importance. The low OR for "dipstick hematuria, year prior" [rows 49 and 61] might reflect two sub-populations: women (some menstruating) and men (hematuria always abnormal).

2.2.1 Bias correction

Mechanical ventilation and vasopressors showed the largest RRs, consistent with findings that AKI in veterans with COVID-19 varied with severity of illness [61]. Verbeek et al recommended correcting bias in observed RR using the "reference confounder" with the largest effect [62]. Unconfounding the *APOL1* RR of AKI with vasopressors alone reduced the RR to 1.09, **Fig 9**.

Bias correction for reference confounders

Relative risk (RR) of AKI in high-risk vs low-risk APOL1 in veterans hospitalized with COVID-19

	No.	AKI (outcome)		Mechanical ventilation		Vasopressors	
APOL1 risk variant group (exposure)							
High-risk (2 RVs alleles)	125	64	51.2%	22	17.6%	17	13.6%
Low-risk (1 or 0 RV alleles)	865	328	37.9%	119	13.8%	81	9.4%
RR, high-risk to low-risk APOL1			**1.35**		**1.28**		**1.45**
Mechanical ventilation							
With	141	112	79.4%				
Without	849	280	33.0%				
RR, with to without mechanical ventilation			**2.41**				
Vasopressors							
With	98	88	89.8%				
Without	892	304	34.1%				
RR, with to without vasopressors			**2.63**				

"Sensitivity to unmeasured residual plausible confounding"		
RRobs	**1.35**	
E-value	2.04	
Reference confounder		
	Mechanical ventilation	**Vasopressors**
RRco	**2.41**	**2.63**
RRce	**1.28**	**1.45**
Bias Factor (BF)	1.15	1.24
Unconfounded APOL1 relative risk of AKI		
RRobs / BF	1.18	1.09
(see Verbeek et al)		

ABBREVIATIONS: AKI = acute kidney injury, APOL1 = apolipoprotein L1, BF = bias factor, E-value = "how large the effect of a confounder would have to be to reduce an observed RR to the null value" (see Verbeek et al), No. = number, RR = relative risk, RRce = RR of confounder exposure association, RRco = RR of confounder outcome association, RRobs = observed RR, RRobs / BF = unconfounded RR, RV = risk variant.

Fig 9. Bias correction, *APOL1* genotype reference confounders. Because vasopressors and mechanical ventilation had significant *APOL1* exposures and had the largest effects on AKI outcomes, their effect could be unconfounded from the raw data for relative risk (RR) of *APOL1* genotypes (high-risk

Fig 9 (continued). versus low-risk). The correlation between Mechanical Ventilation and Vasopressors was not 100 percent, so adjustment for both would move unconfounded *APOL1* RR of AKI even closer to unity.

2.3 *APOL1* and N264K

A second important study by Hung et al of 121,000 from the Million Veteran Program with "African ancestry" (13.8% female) compared CKD in patients with *APOL1* HR versus LR and with and without N264K (a second-site *APOL1* variant) and noted, "presence of a single copy of the *APOL1* p.N264K mutation mitigated the increased risk conferred by two APOL1 HR variants" [63]. About 20% of their data came from smaller studies in the general population, but our re-analysis used only 80% of their data, from veterans.

Fig 10 shows the percentage of subjects by kidney outcomes for the four combinations of *APOL1* HR or LR and N264K alleles present (**+**) or absent (**-**) [63]. Black bars, representing *APOL1* high-risk genotype without N264K (*APOL1* HR, N264K-), show the highest rate for every kidney outcome. Blue bars represent the largest group, *APOL1* low-risk genotype without N264K (*APOL1* LR, N264K-). Note that presence of the N264K allele (N264K**+**) in just 3.8% of *APOL1* LR and 0.5% of *APOL1* HR patients means orange and green bars combined represent less than 5% of subjects, with small absolute numbers (population times rate) in their CKD and outcome groups.



	No. (% of total)	CKD after enrollment	Proteinuria ≥ 1+	CKD prior to enrollment	KF after enrollment	Nephrotic Syndrome	KF prior to enrollment	FSGS
APOL1 LR, N264K-	**101,216 (83.3%)**	**6.21%**	**12.59%**	**13.06%**	**1.51%**	**0.68%**	**1.43%**	**0.08%**
APOL1 HR, N264K-	**15,022 (12.4%)**	**6.44%**	**15.84%**	**17.82%**	**2.49%**	**1.27%**	**4.53%**	**0.35%**
APOL1 LR, N264K+	4,672 (3.8%)	5.63%	12.61%	13.31%	1.63%	0.75%	1.28%	0.06%
APOL1 HR, N264K+	582 (0.5%)	6.36%	14.60%	10.82%	0.69%	0.69%	1.72%	0.17%

NOTE: Million Veteran Program "enrollment" includes approximately annual research newsletters and updates with contact information to maintain "engagement". **ABBREVIATIONS:** APOL1 = apolipoprotein L1, CKD = chronic kidney disease, FS = focal segmental, HR = high-risk, KF = kidney failure, LR = low risk, OR = Odds Ratio (APOL1 HR, N264K- vs APOL1 LR, N264K-).

Fig 10. CKD and kidney outcomes in veterans by *APOL1* and N264K status. Ordered by odds ratio (OR) of kidney outcome between the two large groups, *APOL1* genotype (low-risk versus high-risk) without N264K alleles (N264K-). The data show marked improvement in outcomes after enrollment in the Million Veteran Program. Note that combined subgroups positive for N264K allele (N264K+) represent less than 5% of all subjects.

The chart is ordered by OR between the two largest groups <u>without</u> N264K (N264K-), representing 95% of Black veteran subjects and differing only by *APOL1* HR vs LR. Note for *APOL1* HR N264K- the association of lower rates of KF and CKD after than before Million Veteran Program "enrollment" [64] and that, after enrollment, rates of CKD were the same for all four groups.

3. DISCUSSION

Bioethical oversight of 'race' falls under a principle defined after decades of misuse of 'race' by the US Public Health Service [65,66], **Fig 11**. Yet, misuse of 'race' as a conscious or unconscious input for clinical care persists, even among those aware of its scientific invalidity [67]. Because 'race' is a myth, racialized data can wrongly suggest different outcomes by socially constructed 'race'. From any continent, studies under equal conditions (e.g., even so-called "single race" studies) should be equally informative. The lowest KF mortality rate (i.e, of the most privileged group in the ideal environment) should be the goal for all—different outcomes reflect social inequality.

Institutional review of bioethical principles in US medical research			
Concern	**Human subjects**	**Health information**	**Misuse of 'race'**
Bioethical principle	**Autonomy**	**Privacy**	**Justice**
Date of original legislation	US National Research Act **1974**	US Health Insurance Portability and Accountability Act **1996**	US Constitution Fourteenth Amendment **1868**
IRB oversight	**Strict**	**Strict**	
Federal budget	National Institutes of Health **$52 billion 2022**	Nominal	Medicare expenses for CKD + KF **$123 billion 2020**
'Racial' disparity	**Poorer outcomes by 'race'** Systemic misuse of 'race'	**No physical threat**	**Tripled kidney failure risk** for US Black patients
Health literacy	**Significant health illiteracy** regardless of 'race'	Indirect	**Doubled reading failure** in US hypersegregated schools
Population at risk	"…children, prisoners, impaired decision-making, **economically or educationally disadvantaged"**	**No physical threat**	**Economic, educational, and healthcare deprivation** of uniquely hypersegregated US Black neighborhoods
ABBREVIATIONS: CKD = chronic kidney disease, IRB = institutional review board, KF = kidney failure, Medicare exp. CKD + KF = total Medicare expenses for CKD plus KF, 'race' = United States social taxonomy of 'race'.			

Fig 11. Bioethics: Autonomy, privacy, and justice in United States (US) healthcare. In the US, 'race' is collected to monitor progress in addressing 'racial' disparities in healthcare outcomes but often misused in clinical care. Despite vulnerabilities and inequities related to 'race', the principal of Justice has not spurred oversight.

The Food and Drug Administration's approval of race-specific medicines "has not been challenged as a Fourteenth Amendment violation" [68,69,27], and voluntary corrective guidelines "have had little effect on how these concepts are deployed" [70]. Even the comprehensive, scholarly NASEM recommendations are voluntary [9].

A study of 1,000 randomly selected Cochrane Reviews, published between 2000 and 2018, showed that only 14 (1.4%) had planned to include subgroup analysis by 'race' [71], and in those 14, there was only a single 'racial' finding of statistical significance. Despite centuries of claims of biological differences, 'race' was absent under the high standards of the Cochrane Reviews.

To avoid perpetuating false notions of biological 'race' [72,73,74], we often label it "socially constructed" and always put 'race' or 'racial' in quotation marks [75,76].

3.1 Removing 'race correction'

Our re-analysis found Black and White veterans share the same curve for KF, suggesting cofactors of veteran status minimized 'racial' disparities, **Fig 6**.

3.1.1 Comparable conditions

Implied (but typically unstated) in studies of US veterans are the educational and physical selection standards of the US Armed Services [77]. Long before veterans enrolled in research, servicemembers met written requirements that screen out most of the widespread US functional illiteracy [78], **Fig 12**, and physical requirements (including urine tests) that allow comparable access to military training and jobs. With rare exceptions, servicemembers earned access to Veterans Administration (VA) Healthcare by completing basic training, entering active duty, and serving honorably. Basic training (e.g., to avoid dehydration) may promote relevant habits in veterans.



Fig 12. Late illiteracy: percentage of Black and White 4th grade students reading below basic level.

The European Commission noted that racial or ethnic discrimination "can lead to a cycle of disadvantage which is frequently passed from one generation to the next" [3]. However, US military communities are integrated, and Black service members fared better than Black civilians on numerous metrics [79]. Black and White veterans had similar employment rates [80] and more similar socioeconomic status, **Fig 4**, in contrast to what Peterson and Krivo showed as the relative advantage/disadvantage of US Black and White neighborhoods [81], **Fig 13**. Actual economics of Black and White veterans might be even closer because socially constructed 'race' can influence residency options. For example, simultaneously holding Adichie's admiration for "the sacrifices of African Americans…. that there's a context" [82] and Smith's awareness of social disapproval for not "behaving in ways coded Black" [83], versus holding "implicit bias in perceptions of crime and disorder", which Sampson and Bean noted, may be "one of the underappreciated causes of continued racial segregation" [84].



Fig 13. Distribution of advantages and disadvantages of US White and Black neighborhoods.

Until confounding factors are characterized and controlled for, analyzing veterans separately from the general population may avoid "Simpson's Paradox". Peterson et al showed higher baseline comorbidities and illness severity yet equal or lower mortality among Black veterans in VA healthcare in all but six diseases [85] (or five, after our re-analysis). Despite a higher COVID-19 infection rate among minority women veterans, Tsai et al found equal complications of mortality, cardiovascular events, or onset of heart disease regardless of 'race' [86].

3.2 'Race' and genetics

3.2.1 Inconsistency of 'race'

'Race', 'mixed race', 'biracial', 'multiracial': these terms are all scientifically invalid inputs for healthcare [9]. The mechanism of action of socially constructed 'race' and *APOL1* genotypes in CKD must account for inconsistencies in folk taxonomies of 'race' [87,88,89,90], for example in places like South Africa [91], Nigeria [82], and Brazil:

> …there appears to be no racial descent rule operational in Brazil and it is possible for two siblings differing in Color to belong to completely diverse racial categories…. asked about their origins (the question admitted multiple responses) <10% of Brazilian black individuals gave Africa as one of their answers [92,93].

'Racial' classification in the US dates to a 1662 statute [94] reflected in this segregation-era Census instruction: "A person of mixed white and Negro blood should be returned as a Negro, no matter how small the percentage of Negro blood" [95,96].

3.2.2 Colorism and *APOL1*

"Colorism" varied the abuse of racism to stratify and stabilize 'racial' hierarchies, correlating increasing pigment with worse deprivation.

> …the most effective way to segregate black people was to "use the dark skin slaves vs. the light skin slaves and the light skin slaves vs. the dark skin slaves."…. Subsequently, colorism became an effective strategy in colonizing and dividing people [97].

The odds of inheriting two, one, or zero copies of *APOL1* RV alleles vary, for example, with the number of great-grandparents of West African origin. With eight high-

risk West African great-grandparents, all with *APOL1* HR genotype (i.e., two RV alleles), a subject will inherit two RV alleles. With only one high-risk great-grandparent, the subject "usually looks white or almost so" [98], but the odds of inheriting RV alleles are 75% for zero copies, 25% for one, and zero for two copies.

In contrast, N264K**+** is more common in Europeans, found in less than 5% of Black patients, and "mutually exclusive with the *APOL1* G1 allele…. the presence of a single copy of the *APOL1* N264K mutation mitigated the increased risk conferred by HR *APOL1* genotypes" [99].

With *APOL1* RVs more common in West Africa and N264K**+** more common in Europe, people with one or the other regional distribution marker likely have different physical appearance and lived experiences. Thus, geographically localized "ancestry markers" can be proxies for 'race', and colorism can be a mechanism stratifying subjects even in ostensibly 'single-race' studies.

3.2.3 Confusing 'race', ethnicity, ancestry, and geography

Commonly used terms for socially constructed population groups are ethnicity in Europe and 'race' in the US. 'Race', ethnicity and ancestry are different (albeit similar and overlapping) concepts and all are subject to misuse.

NASEM recommended against conflating 'race' with ancestry:

> Conclusion 4-2. Using socially constructed groupings indiscriminately in human genetics research can be harmful. Their use reinforces the misconception that differences in social inequities or other factors are caused by innate biological differences and diverts attention from addressing the root causes of those social differences, which compromises the rigor and potential positive effect of the research. **Recommendation 1. Researchers should not use race as a proxy for human genetic variation. In particular, researchers should not assign genetic ancestry group labels to individuals or sets of individuals based on their race, whether self-identified or not** [9].

Hung et al were not clear on what they meant by 'race' but expressed confidence in 'race' and in their use of mathematics and big assumptions about the relationships between 'race' and personal ancestry [59,63]. They described selecting a subset from the Million Veteran Program databank "…with genetic information available, of African ancestry" and used the method of "genetically inferred ancestry" described by Fang et al, in 2019 [100].

NASEM subsequently noted:

> There is a pervasive misconception and belief that humans can be grouped into discrete innate categories…. The illusion of discontinuity between racialized groups has supported a history of typological and hierarchical thinking…. These modes of thinking often spill over to other descent-associated population descriptors such as ethnicity and ancestry (Byeon et al., 2021; Fang et al., 2019). The structure of human genetic variation, though, is the result of human population movement and mixing and so is more related to geography than to any racial or ethnic classification [9].

3.2.4 'Race' in research design

NASEM noted,

> Conclusion 4-8. In the absence of measured environmental factors, researchers often wrongly attribute unexplained phenotypic variance between populations to unmeasured genetic differences. **Recommendation 4. Researchers conducting human genetics studies should directly evaluate the environmental factors or exposures that are of potential relevance to their studies, rather than rely on population descriptors as proxies** [9].

The data from Hung et al are valuable but needed to be explored [59,63]. The 'single-race' study design presupposed an association between genetic biology and 'race', made analytic assumptions, then unconsciously overlooked more direct causes of AKI in the data. Selective reporting on *APOL1* genotypes appeared to justify the myth of 'race' as biology.

The directed acyclic graph (DAG) [101] in **Fig 14** is a causal framework the study might have imagined, in modeling their choices, but with our modifications to show potential "back door paths" that could explain the outcomes better than a direct effect of APOL1. The grey oval represents their focus on biology with no attempt to consider possible differential effects of racism between *APOL1* HR and LR genotypes. Their meta-analysis models included some demographic variables, but none related to education, employment, colorism, socioeconomic status, or any other SDOH, ignoring all the context our re-analysis of veterans suggests is important. Nor did they justify choosing <u>any</u> variables for the analysis, which is important because adding more to a model can introduce selection bias.



Fig 14. Causal directed acyclic graph (DAG) that the study might have imagined (with our modifications). One back door path from *APOL1* to kidney disease is via West African ancestry (i.e., West African ancestry increases odds a person has *APOL1* high-risk copies but also alters physical appearance, and physical appearance feeds discrimination). The study assumed the 10 ancestry principal components (plus other variables in other models) analytically controlled for this to justify focusing on relationships in the shaded area. First, we disagree that ancestry principal components controlled for the back door path via skin tone. Second, even if principal components addressed the confound of skin tone, that does not account for the history of discrimination that is its own confound, including generational wealth as a significant factor. Third, given their regional dependence and low frequencies, the inclusion of both N264K and *APOL1* in one analysis is problematic. This approach leads to redundancy and collinearity, resulting in uninterpretable coefficients.

We found several potential back-door paths. First, darker skin tone and colorism: regional ancestry often has aspects of physical appearance, and our re-analysis suggests back door paths attributable to physical appearance and SDOH that undermine analysis focused solely on biology and genetics. Second, generational wealth: even comparing patients who can all 'pass' as White, Black Americans denied generational wealth had limited opportunities, which the research design did not address (i.e., the problem is more than colorism alone, which also was not addressed).

Third, West African ancestry and the N264K gene: regional distribution of N264K variant, with quite low frequencies in African-American veterans, also likely correlates with physical traits, and because few subjects showed this combination of traits, we do not know whether all combinations truly exist in nature.

3.2.5 Equity and *APOL1*

Roberts noted,

> The issue is not whether genes affect health—of course they do—but whether *genetic difference* explains *racial disparities* in health [102].

The APOL1 mechanism that explains 'racial' differences in KF is unknown [103]. Higher RVs of the *APOL1* gene were identified in all haplotype backgrounds, but the magnitude of their effect was dependent on expression levels. Equity is a confounding factor in all these findings.

'Race' affects COVID outcomes through misdiagnosed lung disease [104,105,106], mismeasured blood oxygen levels [107,108], and inequitable care [109]. The different 'racial' systems in Brazil and the US converge in colorism. However, because links between 'race', skin color, and ancestry varied under different 'racial' systems, a broader range of physical appearances and SDOH might weaken *APOL1* associations with 'race' in the Brazilian population (i.e., more noise in the data) [110]. Given the wide confidence intervals (recalculated from p value and z-statistic) in the Brazilian data [60] and a general caution with accepting the null hypothesis of no difference, we cannot say the ORs are significantly different when comparing the same risk factors between the two samples. However, the remarkably similar ORs between US veterans and Brazilians for a variety of non-genetic covariates support other aspects of personal circumstance as more important than the *APOL1* gene.

Chen et al adjusted for age, sex, and baseline eGFR in a general population study and eliminated correlation between KF and *APOL1* [111]. Grams et al found that 'racial' disparities (e.g., in income and education) explained AKI disparities better than *APOL1* risk genotypes [112]. Grams et al also noted, "the majority of blacks with the high-risk genotype experience eGFR decline similar to blacks without the high-risk genotype" [113].

3.2.6 Focal segmental glomerulosclerosis

Our re-analyses did not conclude that *APOL1* HR genotype has <u>no</u> effect on AKI and CKD. Hung et al showed that *APOL1* HR genotype modestly increased risk of focal segmental glomerulosclerosis (FSGS) in veterans [63], which is consistent with other recent reports [114,115,116,117], including low penetrance [118], which may depend on cumulative effects of multiple cofactors:

> …the development of kidney disease is rare, suggesting the need for a second hit [119].

Veteran status appears to partially mitigate the FSGS risk, leading to relatively few FSGS and KF events, small absolute percentage rates, and ORs within the block of modest ORs, **Figs 8 and 10**.

The risk of stereotyping dark skin as a sign of *APOL1* HR genotype follows trans-Atlantic enslavement of West African people (i.e., descendants of formerly enslaved people—both still living in the US and recently immigrated from Caribbean countries). However, mass migration, globalization, and more recent US immigration fueled by

military and economic conflicts in Central and East African countries continue to diversify African ancestral histories. Even if the likelihood were increased by visual examination, who and when to test for *APOL1* HR genotype may hinge on understanding reduced disparity in veterans. Nonspecific Population Health measures may mitigate accumulated 'second hit(s)' from SDOH—even before any component cofactors are fully characterized.

3.3 Potential implications

Commercial interests drive innovation, but there is also profit potential in misuse of 'race' [120]. Research into low-cost preventive measures and SDOH usually requires government funding, so we highlight three such areas for further study: **(1)** illiteracy and deprivation cofactors (implied by outcome differences between veterans and the general population), **(2)** role of 'race' when searching for genetic causes without an hypothesis, and **(3)** international collaboration on ethics that could discourage misuse of 'race'.

3.3.1 Proxy for illiteracy and deprivation

Illiteracy varies by district, **Fig 12**, and does not cause but is associated with CKD [121,122], implicating broad consequences of reading failure (e.g., difficulty obtaining jobs with US health benefits that are not universal). Up to 90% of high school graduates may be illiterate [123]. A 2001 summary of decades of reading research funded by the National Institute of Child Health and Human Development (NICHD) concluded:

> Failure to develop basic reading skills by age nine predicts a lifetime of illiteracy…. On the other hand, … provision of comprehensive early reading interventions can reduce the percentage of children reading below the basic level in the fourth grade… to six percent or less [124].

In contrast, literacy diminished the association between long-term illness and Black 'race' and removed the predictive power of "education" and being African American [125]. Adult literacy programs did not improve CKD [126], but early intervention can succeed [127,128,129,130]. Further research might prompt literacy testing in medical research [131,132] to prevent 'race' from being a proxy for illiteracy.

Deprivation is associated with CKD [133,134]. The origin of US housing segregation "has now largely been forgotten" [135,136]. However, patients from disadvantaged neighborhoods, **Fig 13** [137], still suffer health effects of childhood poisonings [138,139,140] and prenatal exposures [141,142] that increase CKD risk [143,144,145]. Healthcare access and tracking of serial creatinine may allow early intervention for pre-chronic kidney disease (preCKD) [1]. Further research (e.g., in zip codes of the few White and Black neighborhoods with similar demographics) might show whether early exposures contribute to purported 'racial' disparities in GFR and to "senile nephrosclerosis" found in one-third of young but absent in 10% of elderly kidney donors [146].

3.3.2 Racialized genome-wide associations

Genome-wide association studies (GWASs) search outcomes data without an hypothesis and often without a known mechanism of action. However, structural racism based on pigment (a gene product) may associate socially constructed environmental insults with single-nucleotide polymorphisms (SNPs) in linkage disequilibrium with pigmentary and other racialized genes [147,148]. Colorism may enhance the illusion of 'race' as biology by varying polygenic scores with pigment directly (e.g., through

prenatal and childhood health, education, employment, access); and indirectly (e.g., through circumstances of parents and grandparents), especially confounding GWASs [149]. Associations alone cannot tell whether historical violence against groups of people based on appearance induced heritable changes in gene function through interactions between social environment and gene expression.

Instead of combining Black veteran and Black general populations [150], GWASs comparing their results might reveal SNPs that appear under racialized socioeconomic and gene-environment stresses (e.g., illiteracy, deprivation).

3.3.3 International bioethics

Because 'race' is socially constructed, our research merely confirms well known facts—conclusions of biological 'race' will always be false, and re-analyses will always find social causes. Research providing no explanation for 'racial' differences or no justification for including 'race' beyond "predictive accuracy" is especially problematic. NASEM noted:

> …studies that are poorly designed to answer research questions are scientifically invalid and unethical….
>
> What is necessary is an understanding of the underlying issues during study design and long before data analyses: the moment of publication is far too late [9].

Although studies perpetuate the 'race' myth in ways that are "largely unintentional" [151], Hunt and Megyesi found, in 2008, that most genetics researchers **(1)** understood that 'race' is invalid, **(2)** used 'race' as a proxy for biological cofactors without bothering to explore further (simply assumed cofactors would be difficult to identify and measure), **(3)** could list serious potential negative consequences of misusing 'race', but **(4)** did so anyway [152]. In 2024, "journal editors" encouraged the allowed form of social commentary: genetic scientists rationalizing misuse of socially constructed 'race' [153] to continue publishing BS under "the tranquilizing drug of gradualism" [154]. Their predecessors did the same, 75 years ago:

> For the social scientists gathered by UNESCO to write its 1950 'Statement against race and racial prejudice', race had to be disproved on scientific grounds, a task which they saw as easily achievable. The Statement claimed that:
>
> > The division of the human species into 'races' is partly conventional and partly arbitrary and does not imply any hierarchy whatsoever. Many anthropologists stress the importance of human variation, but believe that 'racial' divisions have limited scientific interest and may even carry the risk of inviting abusive generalization. (UNESCO, 1968: 270)
>
> Directly after the publication of the Statement, it was followed by an alternative Statement written mainly by geneticists also involved in the UNESCO project…. that race continued to be of scientific usefulness for describing 'groups of mankind possessing well-developed and primarily heritable physical differences from other groups' (Comas, 1961: 304) and should not be confused with politics [155].

The American Medical Association (AMA) recently described the determination of its founder…

> …to explicitly exclude women and Black physicians…. [His] role was highly active, not passive, and his choice for a racist direction was pursued with energy and force [156].

Later, as founding editor of *The Journal of the American Medical Association* (JAMA), this racist man established the traditions of medical publishing that blocked study of the role of 'race' in research findings. Like another journal that rejected our claim of relevance (to discuss the role of illiteracy and sociology of deprivation in our research), JAMA is known for excluding discussion of the racism behind socially constructed 'race' and for shunting consideration of social cofactors to "Commentary" [52]. Because advocating change takes more words than "stay the course", modern word, figure, and reference limits also favor the status quo. The NASEM report [9] and persistent misuse of 'race' suggest the philosophy of human medical science that allows these restrictions at many medical journals needs reexamination [157,158,159,**160,161**].

American bioethics favors autonomy almost to the exclusion of its other three founding principles, but as Fins noted, we should "…move beyond narrow questions of patient choice, particularly when the disenfranchised are not in a position to exercise that choice" [162]. Fins added, "…that while rights are necessary to avoid exploitation, they are not sufficient and that instead there should be a focus on capabilities that promote human flourishing" (personal comm). In this case, it is about identifying nascent kidney disease with metrics that are accurate and accountable to scientific and ethical norms [1,9]. Further research might show whether an appeal to international bioethics could end misuse of 'race' in medical research.

4. CONCLUSION

Re-analysis of 'race' reveals cross-cultural conflicts in its social origins such that research associating socially constructed 'race' with any explanation other than structural racism will always be wrong.

Selection and training of servicemembers create comparable starting conditions for veterans. Those in Veterans Administration Healthcare showed comparable social determinants of health and comparable kidney outcomes, which should be the expected norm for all under more equal social conditions—regardless of socially constructed 'race', ethnicity, or nationality. Further research to identify essential veteran cofactors may improve general population health, reduce 'racial' disparities, and redirect some resources to prevention.

Apolipoprotein L1 high-risk variants increase focal segmental glomerulosclerosis, but the increased risk appears too small to justify treatment at the population level. Broad application of nonspecific Population Health measures may further mitigate risk.

Despite scholarly consensus and 100 years of academic articles that biological 'race' is scientifically invalid, misuse persists in medical research, suggesting an hypothesis for further study: we may need to **(1)** work together, **(2)** discourage standing in the doorway, and **(3)** appeal to principles of international bioethics to end misuse of 'race'.

5. METHODS

5.1 Ethics statement

'Race' in research: NASEM advised, "Researchers should be as transparent as possible about the specific procedures used to name groups within their data sets" [9]. We did not present 'race' as an input to clinical decisions, a means of stratifying care, or an hypothesis for genetic difference without data. One primary source used 'race'

designated in Medicare Denominator File or VA data sources [58]. We explored the approach to 'race' and ancestry in the other primary sources (see **Discussion**).

Human subjects: The primary sources used information collected for non-research activities in VA Healthcare or obtained informed consent from all participants after receiving IRB approval. Secondary re-analysis of publicly available data is not considered human subjects research and is exempt from IRB review [163].

Privacy: The study included no individually identifiable patient health information.

5.2 Re-analyses

Our main hypothesis is that because 'race' is socially constructed, social context and social cofactors will remove or explain 'racial' differences in CKD and KF. A corollary is that re-analyzing studies that endorse biological 'race' will always be fruitful. During recent questioning of eGFR 'race corrections', preliminary re-analysis of a study of KF in Black and White veterans elicited references to *APOL1* (e.g., "the kidney failure gene") as "validating" 'racial' difference in kidney disease. We broadened our literature search.

Relevant to our hypothesis, we searched PubMed (on February 24, 2024) for titles or abstracts that included "veteran" and "*APOL1*". Of three studies directly addressing kidney disease, we added re-analysis of two (**Sections 2.2 and 2.3**) and noted the third in Potential Implication for GWASs (**Section 3.3.2**).

Our secondary re-analyses involved extracting primary data of veterans from previously published tables and figures (i.e., data of all subjects in the first and third studies and 80% of subjects in the second), using knowledge of socially constructed 'race' and obvious social cofactors to reorganize the data into simple, accessible graphs and charts to better compare RRs and ORs of CKD rates and KF outcomes.

5.2.1 Re: Removing 'race correction'

The large study of KF in veterans by Choi et al [58] presented enough data to reverse the eGFR 'race correction' (**Section 2.1**). We repurposed data from its first and second tables, removed 'race correction' by dividing MDRD eGFRs by 1.21, and examined eGFR prevalence and rates of KF against eGFR results with and without 'race correction'. Mathematically, transforming a variable by a constant has a one-to-one impact on the magnitude of the regression coefficient [164], and the estimated association will change proportional to that number, which may be useful if an actual difference could be overlooked. However, if no true 'racial' difference exists, the association between eGFR prevalence rates and KF rates for White and Black patients should be similar, and 'race correction' would inflate the association's magnitude, implying more KF than found.

We estimated the association among White patients, Black patients with unadjusted eGFR rates, and the same Black patients with eGFR 'race correction' removed, hypothesizing that the ratio of associations for 'race-corrected' data and 'not-race-corrected' data would equal 1.21, the exact magnitude of 'race correction'. Additionally, we hypothesized that there would not be a significant difference in associations between White and Black patients after removing 'race correction'.

5.2.2 Veteran and *APOL1*

Re: *APOL1*, AKI, and COVID: We re-analyzed a study by Hung et al [59], calculating RR and OR from primary data in their first and second tables. Although we dismissed this article in an early version of this manuscript (due to uneven distribution of vasopressors and mechanical ventilation between those with and without AKI), repeated

encounters with references to it as “proof” that genetic susceptibility causes ‘racial’ disparity prompted our full re-analysis and PubMed search.

We adjusted the *APOL1* RR to remove the confounding of high-impact cofactors. For comparison, we included a similar study in the Brazilian general population [60], where ‘race’ is defined differently. Because some CIs were unusually asymmetric, we recalculated them from the given p values and z-statistics.

Re: *APOL1* and N264K: We similarly re-analyzed another study by Hung et al [63] that examined associations between *APOL1* LR and HR genotypes, N264K variants, and the US taxonomy of socially constructed ‘race’. We focused on the data from US veterans (the bulk of their data) and created simple graphs to better show the relationships within the data. Because N264K**+** is an *APOL1* variant more common in Europe (occurring in less than 5% of US Black veterans), we further narrowed to the 95% of Black veterans without N264K, calculating and ordering results by ORs between the LR and HR (N264K**-**) subgroups.

ACKNOWLEDGMENTS

In memory of Rear Admiral W. Norman Johnson and many others who endured kidney failure after being prescribed nephrotoxic drugs that might have been avoided with early warning and caution, and of the Rev. Dr. Canon Cyril C. Burke, Sr., who taught ethics and whose final medical care was complicated by ‘race’.

The authors gratefully acknowledge Edward Feller, MD, FACP, FACG, Ruth Levy Guyer, PhD, James M. Gilchrist, Professor Emeritus of Neurology at Southern Illinois University School of Medicine, and anonymous colleagues for critical review of a draft of this article, and Joseph J. Fins, MD, MACP, FRCP, and John C. Kotelly, PhD, US Air Force mathematician (ret.), for their insights.

Competing Interests

The authors have declared that no competing interests exist.

Funding

The authors received no specific funding for this work.

REFERENCES

1. Burke CO, Tanzer JR, Toffaletti JG, Burke LM. Pre-chronic kidney disease: Serial creatinine tracks glomerular filtration rate decline above 60 mL/min. medRxiv preprint doi: 10.1101/2024.09.17.24313678

2. Hunt LM, Truesdell ND, Kreiner MJ. Genes, race, and culture in clinical care: racial profiling in the management of chronic illness. Med Anthropol Q. 2013 Jun;27(2):253-71. doi: 10.1111/maq.12026. Epub 2013 Jun 26. PMID: 23804331; PMCID: PMC4362784.

3. European Commission: Directorate-General for Justice and Consumers, Farkas L. The meaning of racial or ethnic origin in EU law : between stereotypes and identities. Publications Office; 2017. Available from: doi/10.2838/83148

4. Zaslavsky AM, Ayanian JZ, Zaborski LB. The validity of race and ethnicity in enrollment data for Medicare beneficiaries. Health Serv Res. 2012 Jun;47(3 Pt 2):1300-21. doi: 10.1111/j.1475-6773.2012.01411.x. Epub 2012 Apr 19. PMID: 22515953; PMCID: PMC3349013.

5. Arias E, Schauman WS, Eschbach K, Sorlie PD, Backlund E. The validity of race and Hispanic origin reporting on death certificates in the United States. Vital Health Stat 2. 2008 Oct;(148):1-23. PMID: 19024798.

6. Clarke LC, Rull RP, Ayanian JZ, Boer R, Deapen D, West DW, Kahn KL. Validity of Race, Ethnicity, and National Origin in Population-based Cancer Registries and Rapid Case Ascertainment Enhanced With a Spanish Surname List. Med Care. 2016 Jan;54(1):e1-8. doi: 10.1097/MLR.0b013e3182a30350. PMID: 23938598; PMCID: PMC4449309.

7. Martino SC, Elliott MN, Haas A, Peltz A, Saliba D, Hassan S, Rothenberg E, Keshawarz A, Rushkin M, Gildner J, Orr N, Hager M, Myers R, Kiser R, Bernheim S. Assessing the accuracy of race-and-ethnicity data in the Outcome and Assessment Information Set. J Am Geriatr Soc. 2024 Aug;72(8):2508-2515. doi: 10.1111/jgs.18889. Epub 2024 Mar 21. PMID: 38511724.

8. Lu C, Ahmed R, Lamri A, Anand SS. Use of race, ethnicity, and ancestry data in health research. PLOS Glob Public Health. 2022 Sep 15;2(9):e0001060. doi: 10.1371/journal.pgph.0001060. PMID: 36962630; PMCID: PMC10022242.

9. National Academies of Sciences, Engineering, and Medicine. Using Population Descriptors in Genetics and Genomics Research: A New Framework for an Evolving Field. Washington, DC: National Academies Press (US), 2023 Mar 14. PMID: 36989389. doi: 10.17226/26902.

10. Schneider EC, Shah A, Doty MM, Tikkanen R, Fields K, Williams II RD. Mirror, Mirror 2021 — Reflecting Poorly: Health Care in the U.S. Compared to Other High-Income Countries. Commonwealth Fund, Aug. 2021. doi: 10.26099/01dv-h208.

11. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020 Feb 29;395(10225):709-733. doi: 10.1016/S0140-6736(20)30045-3. Epub 2020 Feb 13. PMID: 32061315; PMCID: PMC7049905.

12. Institute of Medicine (US) Committee to Study Decision Making; Hanna KE, editor. Biomedical Politics. Washington (DC): National Academies Press (US); 1991. Origins of the Medicare Kidney Disease Entitlement: The Social Security Amendments of 1972. Available from: https://www.ncbi.nlm.nih.gov/books/NBK234191/

13. United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020. [cited 2022 November 25]. Available from: https://usrds-adr.niddk.nih.gov/2022

14. Galvani AP, Parpia AS, Pandey A, Sah P, Colón K, Friedman G, et al. Universal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic. Proc Natl Acad Sci U S A. 2022 Jun 21;119(25):e2200536119. doi: 10.1073/pnas.2200536119. Epub 2022 Jun 13. PMID: 35696578; PMCID: PMC9231482.

15. Lee DC, Liang H, Shi L. The convergence of racial and income disparities in health insurance coverage in the United States. Int J Equity Health. 2021 Apr 7;20(1):96. doi: 10.1186/s12939-021-01436-z. PMID: 33827600; PMCID: PMC8025443.

16. Racial Inclusivity of U.S. News Honor Roll Hospitals. In 2021 Winning Hospitals: Racial Inclusivity. The Lown Institute [online]. 2022 March 17 [cited 2022 March 27]. Available from: https://lownhospitalsindex.org/

17. Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Smedley BD, Stith AY, Nelson AR, editors. Washington (DC): National Academies Press (US); 2003. PMID: 25032386.

18. McFarling UL. 20 years ago, a landmark report spotlighted systemic racism in medicine. Why has so little changed? Stat News. 2022 February 23 [cited 2023 June 6]. Available from: https://www.statnews.com/2022/02/23/landmark-report-systemic-racism-medicine-so-little-has-changed/

19. Albertus P, Morgenstern H, Robinson B, Saran R. Risk of ESRD in the United States. Am J Kidney Dis. 2016 Dec;68(6):862-872. doi: 10.1053/j.ajkd.2016.05.030. Epub 2016 Aug 28. PMID: 27578184; PMCID: PMC5123906.

20. National Safety Council estimates based on data from National Center for Health Statistics – Mortality Data for 2019, population and life expectancy data from the U.S. Census Bureau, deaths classified on the basis of the 10th Revision of the World Health Organization's "The International Classification of Diseases" (ICD) [Cited 2021 December 31]. Available from: https://injuryfacts.nsc.org/all-injuries/preventable-death-overview/odds-of-dying/

21. Norris KC, Williams SF, Rhee CM, Nicholas SB, Kovesdy CP, Kalantar-Zadeh K, et al. Hemodialysis Disparities in African Americans: The Deeply Integrated Concept of Race in the Social Fabric of Our Society. Semin Dial. 2017 May;30(3):213-223. doi: 10.1111/sdi.12589. Epub 2017 Mar 9. PMID: 28281281; PMCID: PMC5418094.

22. Benjamins MR, Lorenz P, Saiyed NS, Silva A, Mattix-Kramer HJ, Pys P, Schulz A. Black-White Inequities in Kidney Disease Mortality Across the 30 Most Populous US Cities. J Gen Intern Med. 2022 May;37(6):1351-1358. doi: 10.1007/s11606-022-07444-1. Epub 2022 Mar 9. PMID: 35266122; PMCID: PMC9086025.

23. LaVeist TA, Pérez-Stable EJ, Richard P, Anderson A, Isaac LA, Santiago R, et al. The Economic Burden of Racial, Ethnic, and Educational Health Inequities in the US. JAMA. 2023 May 16;329(19):1682-1692. doi: 10.1001/jama.2023.5965. Erratum in: JAMA. 2023 Jun 6;329(21):1886. PMID: 37191700.

24. Vyas DA, Eisenstein LG, Jones DS. Hidden in Plain Sight - Reconsidering the Use of Race Correction in Clinical Algorithms. N Engl J Med. 2020 Aug 27;383(9):874-882. doi: 10.1056/NEJMms2004740. Epub 2020 Jun 17. PMID: 32853499.

25. Singh S. Racial biases in healthcare: Examining the contributions of Point of Care tools and unintended practitioner bias to patient treatment and diagnosis. Health (London). 2021 Dec 7:13634593211061215. doi: 10.1177/13634593211061215. Epub ahead of print. PMID: 34875900.

26. Cerdeña JP, Asabor EN, Plaisime MV, Hardeman RR. Race-based medicine in the point-of-care clinical resource UpToDate: A systematic content analysis. EClinicalMedicine. 2022 Jul 29;52:101581. doi: 10.1016/j.eclinm.2022.101581. PMID: 35923427; PMCID: PMC9340501.

27. Hunt LM, Kreiner MJ. Pharmacogenetics in primary care: the promise of personalized medicine and the reality of racial profiling. Cult Med Psychiatry. 2013 Mar;37(1):226-35. doi: 10.1007/s11013-012-9303-x. PMID: 23264029; PMCID: PMC3593998.

28. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):1269-1324. doi: 10.1161/HYP.0000000000000066. Epub 2017 Nov 13. Erratum in: Hypertension. 2018 Jun;71(6):e136-e139. Erratum in: Hypertension. 2018 Sep;72(3):e33. PMID: 29133354.

29. Holt HK, Gildengorin G, Karliner L, Fontil V, Pramanik R, Potter MB. Differences in Hypertension Medication Prescribing for Black Americans and Their Association with Hypertension Outcomes. J Am Board Fam Med. 2022 Jan-Feb;35(1):26-34. doi: 10.3122/jabfm.2022.01.210276. PMID: 35039409.

30. Fitzpatrick JK, Yang J, Ambrosy AP, Cabrera C, Stefansson BV, Greasley PJ, et al. Loop and thiazide diuretic use and risk of chronic kidney disease progression: a multicentre observational cohort study. BMJ Open. 2022 Jan 31;12(1):e048755. doi: 10.1136/bmjopen-2021-048755. PMID: 35105612; PMCID: PMC8808372.

31. SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9. Erratum in: N Engl J Med. 2017 Dec 21;377(25):2506. PMID: 26551272; PMCID: PMC4689591.

32. Rocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB, Wall BM, et al; SPRINT Research Group. Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis. 2018 Mar;71(3):352-361. doi: 10.1053/j.ajkd.2017.08.021. Epub 2017 Nov 20. PMID: 29162340; PMCID: PMC5828778.

33. Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. N Engl J Med. 2021 Dec 30;385(27):2507-2519. doi: 10.1056/NEJMoa2110730. Epub 2021 Nov 5. PMID: 34739197.

34. Mehta RL, Burdmann EA, Cerdá J, Feehally J, Finkelstein F, García-García G, et al. Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 Global Snapshot: a multinational cross-sectional study. Lancet. 2016 May 14;387(10032):2017-25. doi: 10.1016/S0140-6736(16)30240-9. Epub 2016 Apr 13. Erratum in: Lancet. 2016 May 14;387(10032):1998. PMID: 27086173.

35. Wang HW, Jiang MY. Higher volume of water intake is associated with lower risk of albuminuria and chronic kidney disease. Medicine (Baltimore). 2021 May 21;100(20):e26009. doi: 10.1097/MD.0000000000026009. PMID: 34011099; PMCID: PMC8137104.

36. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect. 2005 Feb;113(2):192-200. doi: 10.1289/ehp.7337. PMID: 15687057; PMCID: PMC1277864.

37. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar 16;130(6):461-70. doi: 10.7326/0003-4819-130-6-199903160-00002. PMID: 10075613.

38. Stevens LA, Claybon MA, Schmid CH, Chen J, Horio M, Imai E, et al. Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney Int. 2011 Mar;79(5):555-62. doi: 10.1038/ki.2010.462. Epub 2010 Nov 24. PMID: 21107446; PMCID: PMC4220293.

39. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al, and Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009 Jun;53(6):982-92. doi: 10.1053/j.ajkd.2008.12.034. Epub 2009 Apr 1. PMID: 19339088.

40. Lee CS, Cha RH, Lim YH, Kim H, Song KH, Gu N, et al. Ethnic coefficients for glomerular filtration rate estimation by the Modification of Diet in Renal Disease study equations in the Korean population. J Korean Med Sci. 2010 Nov;25(11):1616-25. doi: 10.3346/jkms.2010.25.11.1616. Epub 2010 Oct 26. PMID: 21060751; PMCID: PMC2966999.

41. Praditpornsilpa K, Townamchai N, Chaiwatanarat T, Tiranathanagul K, Katawatin P, Susantitaphong P, et al. The need for robust validation for MDRD-based glomerular filtration rate estimation in various CKD populations. Nephrol Dial Transplant. 2011 Sep;26(9):2780-5. doi: 10.1093/ndt/gfq815. Epub 2011 Feb 28. PMID: 21357214.

42. Liu X, Gan X, Chen J, Lv L, Li M, Lou T. A new modified CKD-EPI equation for Chinese patients with type 2 diabetes. PLoS One. 2014 Oct 14;9(10):e109743. doi: 10.1371/journal.pone.0109743. PMID: 25313918; PMCID: PMC4196932.

43. Martin T. The color of kidneys. Am J Kidney Dis. 2011 Nov;58(5):xxvii-xxviii. doi: 10.1053/j.ajkd.2011.08.018. PMID: 22014639.

44. Teo BW, Xu H, Wang D, Li J, Sinha AK, Shuter B, Sethi S, Lee EJ. GFR estimating equations in a multiethnic Asian population. Am J Kidney Dis. 2011 Jul;58(1):56-63. doi: 10.1053/j.ajkd.2011.02.393. Epub 2011 May 20. PMID: 21601325.

45. Umeukeje EM, Koonce TY, Kusnoor SV, Ulasi II, Kostelanetz S, Williams AM, et al. Systematic review of international studies evaluating MDRD and CKD-EPI estimated glomerular filtration rate (eGFR) equations in Black adults. PLoS One. 2022 Oct 18;17(10):e0276252. doi: 10.1371/journal.pone.0276252. PMID: 36256652; PMCID: PMC9578594.

46. Eneanya ND, Boulware LE, Tsai J, Bruce MA, Ford CL, Harris C, et al. Health inequities and the inappropriate use of race in nephrology. Nat Rev Nephrol. 2022 Feb;18(2):84-94. doi: 10.1038/s41581-021-00501-8. Epub 2021 Nov 8. PMID: 34750551; PMCID: PMC8574929.

47. Hsu CY. Eliminating the race coefficient in kidney function estimating equations: The center did hold. Trans Am Clin Climatol Assoc. 2023;133:247-261. PMID: 37701614; PMCID: PMC10493757.

48. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al; Chronic Kidney Disease Epidemiology Collaboration. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021 Nov 4;385(19):1737-1749. doi: 10.1056/NEJMoa2102953. Epub 2021 Sep 23. PMID: 34554658.

49. Björk J, Grubb A, Sterner G, Nyman U. A new tool for predicting the probability of chronic kidney disease from a specific value of estimated GFR. Scand J Clin Lab Invest. 2010 Sep;70(5):327-33. doi: 10.3109/00365513.2010.488699. PMID: 20545460.

50. Kasozi RN, Meeusen JW, Lieske JC. Estimating glomerular filtration rate with new equations: can one size ever fit all? Crit Rev Clin Lab Sci. 2023 Nov;60(7):549-559. doi: 10.1080/10408363.2023.2214812. Epub 2023 Jun 1. PMID: 37259709; PMCID: PMC10592396.

51. Kuhn TS. The structure of scientific revolutions, 4th ed. Chicago, IL: The University of Chicago Press; 2012.

52. McFarling UL. Troubling podcast puts JAMA, the 'voice of medicine,' under fire for its mishandling of race. Stat News. 2021 April 6 [Cited 2022 August 31]. Available from: https://www.statnews.com/2021/04/06/podcast-puts-jama-under-fire-for-mishandling-of-race/

53. Chander, A. (2016). The racist algorithm. Mich. L. Rev., 115, 1023. Available from: https://repository.law.umich.edu/cgi/viewcontent.cgi?article=1657&context=mlr

54. Williams P. Retaining Race in Chronic Kidney Disease Diagnosis and Treatment. Cureus. 2023 Sep 11;15(9):e45054. doi: 10.7759/cureus.45054. PMID: 37701164; PMCID: PMC10495104.

55. Watson-Daniels J. Algorithmic Fairness and Color-blind Racism: Navigating the Intersection. arXiv preprint, 2024. arXiv:2402.07778. Available from: https://arxiv.org/pdf/2402.07778

56. Desai, J., Watson, D., Wang, V., Taddeo, M., & Floridi, L. (2022). The epistemological foundations of data science: a critical review. Synthese, 200(6), 469. Available from: https://link.springer.com/article/10.1007/s11229-022-03933-2

57. Lincoln A. Second Inaugural Address, 1865. Available from: https://www.gilderlehrman.org/history-resources/spotlight-primary-source/president-lincolns-second-inaugural-address-1865

58. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Hernandez GT, O'Hare AM. White/black racial differences in risk of end-stage renal disease and death. Am J Med. 2009 Jul;122(7):672-8. doi: 10.1016/j.amjmed.2008.11.021. PMID: 19559170; PMCID: PMC2749005.

59. Hung AM, Shah SC, Bick AG, Yu Z, Chen HC, Hunt CM, et al; VA Million Veteran Program COVID-19 Science Initiative. APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program. JAMA Intern Med. 2022 Apr 1;182(4):386-395. doi: 10.1001/jamainternmed.2021.8538. PMID: 35089317; PMCID: PMC8980930.

60. de Almeida DC, Franco MDCP, Dos Santos DRP, Santos MC, Maltoni IS, Mascotte F, et al. Acute kidney injury: Incidence, risk factors, and outcomes in severe COVID-19 patients. PLoS One. 2021 May 25;16(5):e0251048. doi: 10.1371/journal.pone.0251048. PMID: 34033655; PMCID: PMC8148326.

61. Bowe B, Xie Y, Xu E, Al-Aly Z. Kidney Outcomes in Long COVID. J Am Soc Nephrol. 2021 Nov;32(11):2851-2862. doi: 10.1681/ASN.2021060734. Epub 2021 Sep 1. PMID: 34470828; PMCID: PMC8806085.

62. Verbeek JH, Whaley P, Morgan RL, Taylor KW, Rooney AA, Schwingshackl L, et al; GRADE Working Group. An approach to quantifying the potential importance of residual confounding in systematic reviews of observational studies: A GRADE concept paper. Environ Int. 2021 Dec;157:106868. doi: 10.1016/j.envint.2021.106868. Epub 2021 Sep 13. PMID: 34530289.

63. Hung AM, Assimon VA, Chen HC, Yu Z, Vlasschaert C, Triozzi JL, et al; Million Veteran Program. Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease. J Am Soc Nephrol. 2023 Nov 1;34(11):1889-1899. doi: 10.1681/ASN.0000000000000219. Epub 2023 Oct 6. PMID: 37798822; PMCID: PMC10631602.

64. Gaziano JM, Concato J, Brophy M, Fiore L, Pyarajan S, Breeling J, et al. Million Veteran Program: A mega-biobank to study genetic influences on health and disease. J Clin Epidemiol. 2016 Feb;70:214-23. doi: 10.1016/j.jclinepi.2015.09.016. Epub 2015 Oct 9. PMID: 26441289.

65. Boyd RW, Lindo EG, Weeks LD, McLemore MR. On Racism: A New Standard For Publishing On Racial Health Inequities. Health Affairs Blog, 2020 July 2 [cited 2024 January 24]. Available from: https://www.healthaffairs.org/content/forefront/racism-new-standard-publishing-racial-health-inequities

66. Gamble VN. Under the shadow of Tuskegee: African Americans and health care. Am J Public Health. 1997 Nov;87(11):1773-8. doi: 10.2105/ajph.87.11.1773. PMID: 9366634; PMCID: PMC1381160.

67. Ibrahim Z, Brown C, Crow B, Roumimper H, Kureshi S. The Propagation of Race and Racial Differences as Biological in Preclinical Education. Med Sci Educ. 2022 Jan 10;32(1):209-219. doi: 10.1007/s40670-021-01457-x. PMID: 35186437; PMCID: PMC8814266.

68. Roberts DE. Reconciling Equal Protection Law in the Public and in the Family: The Role of Racial Politics. University of Pennsylvania Law School, Legal Scholarship Repository, Faculty Scholarship, Paper 1624. 2014 [cited 2022 July 5]. Available from: http://scholarship.law.upenn.edu/faculty_scholarship/1624

69. Mulinari S, Bredström A. “Black race”, “Schwarze Hautfarbe”, “Origine africaine”, or “Etnia nera”? The absent presence of race in European pharmaceutical regulation. BioSocieties. 2022 Dec 14. doi: 10.1057/s41292-022-00291-7

70. Bentz M, Saperstein A, Fullerton SM, Shim JK, Lee SS. Conflating race and ancestry: Tracing decision points about population descriptors over the precision medicine research life course. HGG Adv. 2024 Jan 11;5(1):100243. doi: 10.1016/j.xhgg.2023.100243. Epub 2023 Sep 27. PMID: 37771152; PMCID: PMC10585473.

71. Liu P, Ross JS, Ioannidis JP, Dhruva SS, Vasiliou V, Wallach JD. Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews. Clin Trials. 2020 Apr;17(2):231-234. doi: 10.1177/1740774519887148. Epub 2019 Nov 10. PMID: 31709809.

72. Gates HL Jr, Curran AS. Who’s Black and why?: a hidden chapter from the eighteenth-century invention of race. The Belknap Press of Harvard University Press, 2022.

73. Jacoby J. Science says race isn’t real. How long will the US Census keep pretending otherwise? The Boston Globe. 2024 April 7 [cited 2024 April 7]. Available from: https://www.bostonglobe.com/2024/04/07/opinion/census-race-mena-hispanic-latino/

74. Trent S. Race isn’t real, science says. Advocates want the census to reflect that. The Washington Post. 2023 October 16 [cited 2023 October 16]. Available from: https://www.washingtonpost.com/dc-md-va/2023/10/16/census-race-eliminate-race-box/

75. Hodge JL. Invitation to a Dialogue: The Myth of ‘Race.’ The New York Times. 2013 July 16 [cited 2021 December 31]. Available from: http://www.nytimes.com/2013/07/17/opinion/invitation-to-a-dialogue-the-myth-of-race.html

76. Matshidze KP, Richter LM, Ellison GT, Levin JB, McIntyre JA. Caesarean section rates in South Africa: evidence of bias among different ’population groups’. Ethn Health. 1998 Feb-May;3(1-2):71-9. doi: 10.1080/13557858.1998.9961850. PMID: 9673465; PMCID: PMC1876943.

77. Shalikashvili JM, Shelton H, Clark W, Hawley RE, Johnnie E. Wilson JE, et al. Ready, Willing, And Unable To Serve, 75 Percent of Young Adults Cannot Join the Military: Early Education across America is Needed to Ensure National Security. Mission: Readiness, Military Leaders for Kids. 2009 [cited 2022 Jan 20]. Available from: http://cdn.missionreadiness.org/NATEE1109.pdf

78. The 2019 National Assessment of Educational Progress (NAEP). National Center for Education Statistics [Cited 2021 Dec 31]. Available from: https://nces.ed.gov/nationsreportcard/

79. Gupta S. Military towns are the most racially integrated places in the U.S. Here’s why. Science News. 2022 February 8 [Cited 2022 February 18]. Available from: https://www.sciencenews.org/article/military-towns-integration-segregation-united-states

80. Bureau of Labor Statistics: Employment Situation of Veterans – 2019. USDL-20-0452, 2020 March 19 (corrected 2020 Apr 22) [cited 2021 Dec 31]. Available from: https://www.bls.gov/news.release/pdf/vet.pdf

81. Peterson RD, Krivo LJ. Race, Residence, and Violent Crime: A Structure of Inequality. Kansas Law Review, 2009, Vol. 57. Available from: https://kuscholarworks.ku.edu/bitstream/handle/1808/20100/7.0-Peterson_Final.pdf, doi:10.17161/1808.20100

82. Bady A. Chimamanda Ngozi Adichie: “Race doesn’t occur to me.” Salon website. 2013 July 14 [cited 2023 September 17]. Available from: https://www.salon.com/2013/07/14/chimamanda_ngozi_adichie_race_doesnt_occur_to_me_partner/

83. Smith E. There’s a kind of racism embedded in DEI. The Boston Globe. 2024 April 19 [cited 2024 April 19]. Available from: https://www.bostonglobe.com/2024/04/19/opinion/dei-prescriptive-racism/

84. Sampson RJ, Bean L. Cultural Mechanisms and Killing Fields: A Revised Theory of Community-Level Racial Inequality. The Many Colors of Crime: Inequalities of Race, Ethnicity and Crime in America, edited by Ruth Peterson, Lauren Krivo, and John Hagan. New York: New York University Press, 2006. Available from: http://scholar.harvard.edu/files/sampson/files/2006_cultmech_bean.pdf

85. Peterson K, Anderson J, Boundy E, Ferguson L, McCleery E, Waldrip K. Mortality Disparities in Racial/Ethnic Minority Groups in the Veterans Health Administration: An Evidence Review and Map. Am J Public Health. 2018 Mar;108(3):e1-e11. doi: 10.2105/AJPH.2017.304246. PMID: 29412713; PMCID: PMC5803811.

86. Tsai S, Nguyen H, Ebrahimi R, Barbosa MR, Ramanan B, Heitjan DF, et al. COVID-19 associated mortality and cardiovascular disease outcomes among US women veterans. Sci Rep. 2021 Apr 19;11(1):8497. doi: 10.1038/s41598-021-88111-z. PMID: 33875764; PMCID: PMC8055870.

87. Miller G. Cultural Adaptations and Physical Variation: Clines and Folk Taxonomy. Leeward Community College. [cited 2022 September 5]. Available from: https://laulima.hawaii.edu/access/content/user/millerg/anth_150/a150unit3/clinesfolktaxonomy.html

88. Oppenheimer GM. Paradigm lost: race, ethnicity, and the search for a new population taxonomy. Am J Public Health. 2001 Jul;91(7):1049-55. doi: 10.2105/ajph.91.7.1049. PMID: 11441730; PMCID: PMC1446716.

89. Hunt LM, Megyesi MS. The ambiguous meanings of the racial/ethnic categories routinely used in human genetics research. Soc Sci Med. 2008 Jan;66(2):349-61. doi: 10.1016/j.socscimed.2007.08.034. Epub 2007 Oct 23. PMID: 17959289; PMCID: PMC2213883.

90. Deyrup A, Graves JL Jr. Racial Biology and Medical Misconceptions. N Engl J Med. 2022 Feb 10;386(6):501-503. doi: 10.1056/NEJMp2116224. Epub 2022 Feb 5. PMID: 35119803.

91. Posel D. What's in a name? Racial categorisations under apartheid and their afterlife. TRANSFORMATION. 47 (2001); 50-74. ISSN 0258-7696. Available from: http://transformationjournal.org.za/wp-content/uploads/2017/03/tran047005.pdf

92. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):177-82. doi: 10.1073/pnas.0126614100. Epub 2002 Dec 30. PMID: 12509516; PMCID: PMC140919.

93. Travassos C, Williams DR. The concept and measurement of race and their relationship to public health: a review focused on Brazil and the United States. Cad Saude Publica. 2004 May-Jun;20(3):660-78. doi: 10.1590/s0102-311x2004000300003. Epub 2004 May 19. PMID: 15263977.

94. Pokorak JJ. Rape as a Badge of Slavery: The Legal History of, And Remedies for, Prosecutorial Race-of-Victim Charging Disparities. Nevada Law Journal. Vol 7:1. 2006 Fall. Available from: https://scholars.law.unlv.edu/cgi/viewcontent.cgi?article=1418&context=nlj

95. Nobles M. History counts: a comparative analysis of racial/color categorization in US and Brazilian censuses. Am J Public Health. 2000 Nov;90(11):1738-45. doi: 10.2105/ajph.90.11.1738. PMID: 11076243; PMCID: PMC1446411.

96. Braun L, Fausto-Sterling A, Fullwiley D, Hammonds EM, Nelson A, Quivers W, et al. Racial categories in medical practice: how useful are they? PLoS Med. 2007 Sep;4(9):e271. doi: 10.1371/journal.pmed.0040271. PMID: 17896853; PMCID: PMC1989738.

97. Rahman M. The Causes, Contributors, and Consequences of Colorism Among Various Cultures. Wayne State University. 2020 December 14. Available from: https://digitalcommons.wayne.edu/cgi/viewcontent.cgi?article=1069&context=honorstheses

98. Davis FJ. Who is Black? One Nation's Definition. Frontline. 2014 [cited 2024 April 3]. Available from: https://www.pbs.org/wgbh/pages/frontline/shows/jefferson/mixed/onedrop.html

99. Tabachnikov O, Skorecki K, Kruzel-Davila E. APOL1 nephropathy - a population genetics success story. Curr Opin Nephrol Hypertens. 2024 Feb 29. doi: 10.1097/MNH.0000000000000977. Epub ahead of print. PMID: 38415700.

100. Fang H, Hui Q, Lynch J, Honerlaw J, Assimes TL, Huang J, et al; VA Million Veteran Program; Sun YV, Tang H. Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-wide Association Studies. Am J Hum Genet. 2019 Oct 3;105(4):763-772. doi: 10.1016/j.ajhg.2019.08.012. Epub 2019 Sep 26. PMID: 31564439; PMCID: PMC6817526.

101. Lipsky AM, Greenland S. Causal Directed Acyclic Graphs. JAMA. 2022 Mar 15;327(11):1083-1084. doi: 10.1001/jama.2022.1816. PMID: 35226050.

102. Roberts DE. Debating the Cause of Health Disparities: Implications for Bioethics and Racial Equality. University of Pennsylvania Law School, Legal Scholarship Repository, Faculty Scholarship, Paper 573. 2012 [Cited: 2022 July 5]. https://scholarship.law.upenn.edu/faculty_scholarship/573

103. Gupta N, Waas B, Austin D, De Mazière AM, Kujala P, Stockwell AD, et al. Apolipoprotein L1 (APOL1) renal risk variant-mediated podocyte cytotoxicity depends on African haplotype and surface expression. Sci Rep. 2024 Feb 14;14(1):3765. doi: 10.1038/s41598-024-53298-4. PMID: 38355600; PMCID: PMC10866943.

104. Braun L, Grisson R. Race, Lung Function, and the Historical Context of Prediction Equations. JAMA Netw Open. 2023 Jun 1;6(6):e2316128. doi: 10.1001/jamanetworkopen.2023.16128. PMID: 37261833.

105. Moffett AT, Bowerman C, Stanojevic S, Eneanya ND, Halpern SD, Weissman GE. Global, Race-Neutral Reference Equations and Pulmonary Function Test Interpretation. JAMA Netw Open. 2023 Jun 1;6(6):e2316174. doi: 10.1001/jamanetworkopen.2023.16174. PMID: 37261830; PMCID: PMC10236239.

106. Sjoding MW, Ansari S, Valley TS. Origins of Racial and Ethnic Bias in Pulmonary Technologies. Annu Rev Med. 2023 Jan 27;74:401-412. doi: 10.1146/annurev-med-043021-024004. Epub 2022 Jul 28. PMID: 35901314; PMCID: PMC9883596.

107. Valbuena VSM, Seelye S, Sjoding MW, Valley TS, Dickson RP, Gay SE, et al. Racial bias and reproducibility in pulse oximetry among medical and surgical inpatients in general care in the Veterans Health Administration 2013-19: multicenter, retrospective cohort study. BMJ. 2022 Jul 6;378:e069775. doi: 10.1136/bmj-2021-069775. PMID: 35793817; PMCID: PMC9254870.

108. Wong AI, Charpignon M, Kim H, Josef C, de Hond AAH, Fojas JJ, et al. Analysis of Discrepancies Between Pulse Oximetry and Arterial Oxygen Saturation Measurements by Race and Ethnicity and Association With Organ Dysfunction and Mortality. JAMA Netw Open. 2021 Nov 1;4(11):e2131674. doi: 10.1001/jamanetworkopen.2021.31674. Erratum in: JAMA Netw Open. 2022 Feb 1;5(2):e221210. PMID: 34730820; PMCID: PMC9178439.

109. Lee D, Kett PM, Mohammed SA, Frogner BK, Sabin J. Inequitable care delivery toward COVID-19 positive people of color and people with disabilities. PLOS Glob Public Health. 2023 Apr 19;3(4):e0001499. doi: 10.1371/journal.pgph.0001499. PMID: 37074996; PMCID: PMC10115306.

110. Siemens TA, Riella MC, Moraes TP, Riella CV. APOL1 risk variants and kidney disease: what we know so far. J Bras Nefrol. 2018 Oct-Dec;40(4):388-402. doi: 10.1590/2175-8239-JBN-2017-0033. Epub 2018 Jul 26. PMID: 30052698; PMCID: PMC6533999.

111. Chen TK, Coresh J, Daya N, Ballew SH, Tin A, Crews DC, et al. Race, APOL1 Risk Variants, and Clinical Outcomes among Older Adults: The ARIC Study. J Am Geriatr Soc. 2021 Jan;69(1):155-163. doi: 10.1111/jgs.16797. Epub 2020 Sep 7. PMID: 32894582; PMCID: PMC7855571.

112. Grams ME, Matsushita K, Sang Y, Estrella MM, Foster MC, Tin A, et al. Explaining the racial difference in AKI incidence. J Am Soc Nephrol. 2014 Aug;25(8):1834-41. doi: 10.1681/ASN.2013080867. Epub 2014 Apr 10. PMID: 24722442; PMCID: PMC4116065.

113. Grams ME, Rebholz CM, Chen Y, Rawlings AM, Estrella MM, Selvin E, et al. Race, ApoL1 Risk, and eGFR Decline in the General Population. J Am Soc Nephrol. 2016 Sep;27(9):2842-50. doi: 10.1681/ASN.2015070763. Epub 2016 Mar 10. PMID: 26966015; PMCID: PMC5004654.

114. Rosenberg AZ, Kopp JB. Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol. 2017 Mar 7;12(3):502-517. doi: 10.2215/CJN.05960616. Epub 2017 Feb 27. Erratum in: Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1889. doi: 10.2215/CJN.12071018. PMID: 28242845; PMCID: PMC5338705.

115. De Vriese AS, Sethi S, Nath KA, Glassock RJ, Fervenza FC. Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. J Am Soc Nephrol. 2018 Mar;29(3):759-774. doi: 10.1681/ASN.2017090958. Epub 2018 Jan 10. PMID: 29321142; PMCID: PMC5827609.

116. Lepori N, Zand L, Sethi S, Fernandez-Juarez G, Fervenza FC. Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults. Clin Kidney J. 2018 Apr;11(2):179-190. doi: 10.1093/ckj/sfx143. Epub 2018 Jan 9. PMID: 29644057; PMCID: PMC5888331.

117. Bonilla M, Efe O, Selvaskandan H, Lerma EV, Wiegley N. A Review of Focal Segmental Glomerulosclerosis Classification With a Focus on Genetic Associations. Kidney Med. 2024 Apr 17;6(6):100826. doi: 10.1016/j.xkme.2024.100826. PMID: 38765809; PMCID: PMC11099322.

118. Harita Y. Application of next-generation sequencing technology to diagnosis and treatment of focal segmental glomerulosclerosis. Clin Exp Nephrol. 2018 Jun;22(3):491-500. doi: 10.1007/s10157-017-1449-y. Epub 2017 Jul 27. PMID: 28752288; PMCID: PMC5956018.

119. Kallash M, Wang Y, Smith A, Trachtman H, Gbadegesin R, Nester C, et al. Rapid Progression of Focal Segmental Glomerulosclerosis in Patients with High-Risk APOL1 Genotypes. Clin J Am Soc Nephrol. 2023 Mar 1;18(3):344-355. doi: 10.2215/CJN.0000000000000069. Epub 2023 Feb 8. PMID: 36763813; PMCID: PMC10103277.

120. Kahn J. Race, pharmacogenomics, and marketing: putting BiDil in context. Am J Bioeth. 2006 Sep-Oct;6(5):W1-5. doi: 10.1080/15265160600755789. PMID: 16997802.

121. Gurgel do Amaral MS, Reijneveld SA, Geboers B, Navis GJ, Winter AF. Low Health Literacy is Associated with the Onset of CKD during the Life Course. J Am Soc Nephrol. 2021 Jun 1;32(6):1436-1443. doi: 10.1681/ASN.2020081155. Epub 2021 Mar 25. PMID: 33766810; PMCID: PMC8259635.

122. Taylor DM, Fraser S, Dudley C, Oniscu GC, Tomson C, Ravanan R, et al; ATTOM investigators. Health literacy and patient outcomes in chronic kidney disease: a systematic review. Nephrol Dial Transplant. 2018 Sep 1;33(9):1545-1558. doi: 10.1093/ndt/gfx293. PMID: 29165627.

123. Rosenbaum MD, Eidmann KA, Kelley MC, Wheeler JM, Miller BA, Caminker EH, et al. Gary B. v. Snyder ("Detroit Literacy Lawsuit"), Class Action Complaint. United States District Court, Eastern District of Michigan, Southern Division, Civil Action No.: 16-CV-13292, filed 2016 Sep 13 [cited 2021 Dec 31]. Available from: http://www.detroit-accesstoliteracy.org/wp-content/uploads/2016/09/2016-09-13-Complaint.pdf

124. Lyon R. Testimonies to Congress: 1997-2002 [cited 2024 January 13]. Available from: https://eric.ed.gov/?q=%22%22&ft=on&ff1=pubSpeeches%2FMeeting+Papers&ff2=lawElementary+and+Secondary+Education+Act+Title+I&id=ED475205

125. Sentell TL, Halpin HA. Importance of adult literacy in understanding health disparities. J Gen Intern Med. 2006 Aug;21(8):862-6. doi: 10.1111/j.1525-1497.2006.00538.x. PMID: 16881948; PMCID: PMC1831569.

126. Boonstra MD, Reijneveld SA, Foitzik EM, Westerhuis R, Navis G, de Winter AF. How to tackle health literacy problems in chronic kidney disease patients? A systematic review to identify promising intervention targets and strategies. Nephrol Dial Transplant. 2020 Dec 22;36(7):1207–21. doi: 10.1093/ndt/gfaa273. Epub ahead of print. PMID: 33351936; PMCID: PMC8237988.

127. Lyon R. Part 3 1996 Testimony Assembly EdCommittee on Reading/Language Arts/Reid Lyon, NICHD 1991-2005, SES. 1996 [cited 2024 January 13]. Available from: https://www.youtube.com/watch?v=wW1u_MmtSA0

128. Hanford E. Hard Words: Why aren't kids being taught to read? APM Reports. 2018 September 10 [cited 2021 December 31]. Available from: https://www.apmreports.org/episode/2018/09/10/hard-words-why-american-kids-arent-being-taught-to-read

129. Satullo S. Bethlehem schools set a bold reading goal 5 years ago. How close have they gotten? Lehigh Valley Live. 2020 March 10 [Cited 2021 December 31]. Available from: https://www.lehighvalleylive.com/news/2020/03/bethlehem-schools-set-a-bold-reading-goal-5-years-ago-how-close-have-they-gotten.html

130. Merlin M. 'This is proof everybody can do it': Majority of Easton's kindergartners hit benchmarks, regardless of which school they go to. The Morning Call. 2019 Jun 25 [Cited 2021 December 31]. Available from: https://www.mcall.com/news/education/mc-nws-easton-kindergarten-scores-20190625-2iwg43ywdbc5hjcqnjt3izjzk4-story.html

131. Nguyen TH, Paasche-Orlow MK, McCormack LA. The State of the Science of Health Literacy Measurement. Stud Health Technol Inform. 2017;240:17-33. PMID: 28972507; PMCID: PMC6082165.

132. Health Literacy Measurement Tools (Revised). Agency for Healthcare Research and Quality, Rockville, MD. [cited 2021 Dec 31]. Available from: https://www.ahrq.gov/health-literacy/research/tools/index.html

133. Grant CH, Salim E, Lees JS, Stevens KI. Deprivation and chronic kidney disease-a review of the evidence. Clin Kidney J. 2023 Feb 28;16(7):1081-1091. doi: 10.1093/ckj/sfad028. PMID: 37398697; PMCID: PMC10310512.

134. Norton JM, Moxey-Mims MM, Eggers PW, Narva AS, Star RA, Kimmel PL, et al. Social Determinants of Racial Disparities in CKD. J Am Soc Nephrol. 2016 Sep;27(9):2576-95. doi: 10.1681/ASN.2016010027. Epub 2016 May 13. PMID: 27178804; PMCID: PMC5004663.

135. Rothstein R. The Making of Ferguson: Public Policies at the Root of its Troubles. The Economic Policy Institute. 2014 October 15 [cited 2022 May 22]. Available from: https://www.epi.org/publication/making-ferguson/

136. Kemp J, Cisneros H, co-chairs. The Future of Fair Housing: Report of the National Commission on Fair Housing and Equal Opportunity. 2008 December [cited 2022 Jan 20]. Available from: https://www.prrac.org/projects/fair_housing_commission/The_Future_of_Fair_Housing.pdf

137. Baumgartner JC, Aboulafia GN, Getachew Y, et al. Inequities in Health and Health Care in Black and Latinx/Hispanic Communities: 23 Charts. The Commonwealth Fund. 2021 June [cited 2024 February 15]. Available from: https://www.commonwealthfund.org/sites/default/files/2021-06/Baumgartner_racial_disparities_chartbook_v2.pdf

138. Sampson RJ, Winter AS. The Racial Ecology of Lead Poisoning. Du Bois Review: Social Science Research on Race 13 (2016): 261 - 283 [cited 2022 July 19]. Available from: https://www.semanticscholar.org/paper/THE-RACIAL-ECOLOGY-OF-LEAD-POISONING-Sampson-Winter/9cfd36dbbfd11c7b954b887929023ef40db3f403

139. Yeter D, Banks EC, Aschner M. Disparity in Risk Factor Severity for Early Childhood Blood Lead among Predominantly African-American Black Children: The 1999 to 2010 US NHANES. Int J Environ Res Public Health. 2020 Feb 28;17(5):1552. doi: 10.3390/ijerph17051552. PMID: 32121216; PMCID: PMC7084658.

140. Levin R, Zilli Vieira CL, Rosenbaum MH, Bischoff K, Mordarski DC, Brown MJ. The urban lead (Pb) burden in humans, animals and the natural environment. Environ Res. 2021 Feb;193:110377. doi: 10.1016/j.envres.2020.110377. Epub 2020 Oct 28. PMID: 33129862; PMCID: PMC8812512.

141. Politis MD, Yao M, Gennings C, Tamayo-Ortiz M, Valvi D, Kim-Schulze S, et al. Prenatal Metal Exposures and Associations with Kidney Injury Biomarkers in Children. Toxics. 2022 Nov 16;10(11):692. doi: 10.3390/toxics10110692. PMID: 36422900; PMCID: PMC9699100.

142. Sanders AP, Gennings C, Tamayo-Ortiz M, Mistry S, Pantic I, Martinez M, et al. Prenatal and early childhood critical windows for the association of nephrotoxic metal and metalloid mixtures with kidney function. Environ Int. 2022 Aug;166:107361. doi: 10.1016/j.envint.2022.107361. Epub 2022 Jun 27. PMID: 35797845; PMCID: PMC9792626.

143. Rana MN, Tangpong J, Rahman MM. Toxicodynamics of Lead, Cadmium, Mercury and Arsenic-induced kidney toxicity and treatment strategy: A mini review. Toxicol Rep. 2018 May 26;5:704-713. doi: 10.1016/j.toxrep.2018.05.012. PMID: 29992094; PMCID: PMC6035907.

144. Orr SE, Bridges CC. Chronic Kidney Disease and Exposure to Nephrotoxic Metals. Int J Mol Sci. 2017 May 12;18(5):1039. doi: 10.3390/ijms18051039. PMID: 28498320; PMCID: PMC5454951.

145. Reilly R, Spalding S, Walsh B, Wainer J, Pickens S, Royster M, et al. Chronic Environmental and Occupational Lead Exposure and Kidney Function among African Americans: Dallas Lead Project II. Int J Environ Res Public Health. 2018 Dec 14;15(12):2875. doi: 10.3390/ijerph15122875. PMID: 30558242; PMCID: PMC6313544.

146. Rule AD, Cornell LD, Poggio ED. Senile nephrosclerosis--does it explain the decline in glomerular filtration rate with aging? Nephron Physiol. 2011;119 Suppl 1(Suppl 1):p6-11. doi: 10.1159/000328012. Epub 2011 Aug 10. PMID: 21832860; PMCID: PMC3280422.

147. Baxter LL, Watkins-Chow DE, Pavan WJ, Loftus SK. A curated gene list for expanding the horizons of pigmentation biology. Pigment Cell Melanoma Res. 2019 May;32(3):348-358. doi: 10.1111/pcmr.12743. Epub 2018 Nov 6. PMID: 30339321; PMCID: PMC10413850.

148. Durso DF, Bydlowski SP, Hutz MH, Suarez-Kurtz G, Magalhães TR, Pena SD. Association of genetic variants with self-assessed color categories in Brazilians. PLoS One. 2014 Jan 8;9(1):e83926. doi: 10.1371/journal.pone.0083926. PMID: 24416183; PMCID: PMC3885524.

149. Veller C, Coop GM. Interpreting population- and family-based genome-wide association studies in the presence of confounding. PLoS Biol. 2024 Apr 11;22(4):e3002511. doi: 10.1371/journal.pbio.3002511. PMID: 38603516; PMCID: PMC11008796.

150. Robinson-Cohen C, Triozzi JL, Rowan B, He J, Chen HC, Zheng NS, Wei WQ, Wilson OD, Hellwege JN, Tsao PS, Gaziano JM, Bick A, Matheny ME, Chung CP, Lipworth L, Siew ED, Ikizler TA, Tao R, Hung AM. Genome-Wide Association Study of CKD Progression. J Am Soc Nephrol. 2023 Sep 1;34(9):1547-1559. doi: 10.1681/ASN.0000000000000170. Epub 2023 Jun 1. PMID: 37261792; PMCID: PMC10482057.

151. Casad BJ, Luebering JE. “Confirmation bias.” Encyclopedia Britannica. 2024 January 5 [cited 2024 February 4]. Available from: https://www.britannica.com/science/confirmation-bias

152. Hunt LM, Megyesi MS. Genes, race and research ethics: who’s minding the store? J Med Ethics. 2008 Jun;34(6):495-500. doi: 10.1136/jme.2007.021295. PMID: 18511627; PMCID: PMC4362790.

153. Feero WG, Steiner RD, Slavotinek A, Faial T, Bamshad MJ, Austin J, et al. Guidance on use of race, ethnicity, and geographic origin as proxies for genetic ancestry groups in biomedical publications. Am J Hum Genet. 2024 Apr 4;111(4):621-623. doi: 10.1016/j.ajhg.2024.03.003. Epub 2024 Mar 12. PMID: 38479392; PMCID: PMC11023913.

154. King ML Jr. Read Martin Luther King Jr.'s 'I Have a Dream' speech in its entirety. National Public Radio. 2023 January 16 [cited: 2024 April 25]. Available from: https://www.npr.org/2010/01/18/122701268/i-have-a-dream-speech-in-its-entirety

155. Lentin, A. (2008). Europe and the Silence about Race. European Journal of Social Theory, 11(4), 487-503. doi: 10.1177/1368431008097008

156. Madara J. Reckoning with medicine's history of racism. American Medical Association, Leadership Viewpoints. 2021 February 17 [cited 2025 February 6]. Available from: https://www.ama-assn.org/about/leadership/reckoning-medicine-s-history-racism

157. Keeys M, Baca J, Maybank A. Race, Racism, and the Policy of 21st Century Medicine. Yale J Biol Med. 2021 Mar 31;94(1):153-157. PMID: 33795992; PMCID: PMC7995954.

158. Aaron DG, Stanford FC. Medicine, structural racism, and systems. Soc Sci Med. 2022 Apr;298:114856. doi: 10.1016/j.socscimed.2022.114856. Epub 2022 Feb 28. PMID: 35282989; PMCID: PMC9124607.

159. Nuriddin A, Mooney G, White AIR. Reckoning with histories of medical racism and violence in the USA. Lancet. 2020 Oct 3;396(10256):949-951. doi: 10.1016/S0140-6736(20)32032-8. PMID: 33010829; PMCID: PMC7529391.

160. Bassett MT. Public Health Meets the Problem of the Color Line. Am J Public Health. 2017 May;107(5):666-667. doi: 10.2105/AJPH.2017.303714. PMID: 28398798; PMCID: PMC5388967.

161. Bassett MT. #BlackLivesMatter--a challenge to the medical and public health communities. N Engl J Med. 2015 Mar 19;372(12):1085-7. doi: 10.1056/NEJMp1500529. Epub 2015 Feb 18. PMID: 25692912.

162. Fins JJ. COVID-19 makes clear that bioethics must confront health disparities. The Conversation [Internet]. 2020 July 8, 2020 [cited 2022 February 16]. Available from: https://theconversation.com/covid-19-makes-clear-that-bioethics-must-confront-health-disparities-142136

163. 45 CFR 46.104(d). United States Code of Federal Regulations, Title 45 - Public Welfare, Part 46 – Protection of Human Subjects, Subpart A - Basic HHS Policy for Protection of Human Research Subjects, § 46.104(d)(4)(i) - Secondary research for which consent is not required. [cited 2022 April 3]. Available from: https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46#p-46.104(d)(4)(i)

164. Meyer MC. Probability and mathematical statistics: theory, applications, and practice in R. Philadelphia: SIAM; 2019. ISBN: 9781611975789